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General abstract 
Firstly, the aims of the study were to investigate the influences of various factors, sex 
differences, Cytomegalovirus/Epstein-Barr virus (CMV/EBV) serostatus and vitamin D 
concentrations on respiratory illness incidence and immune function during the winter 
months in a student cohort of endurance athletes. In Chapter 3, the findings of the study 
concur with recent reports of illness incidence at major competitive games which indicate 
that female athletes may be more susceptible than their male counterparts to upper respiratory 
tract illness (URTI) symptoms and that lower oral-respiratory mucosal immunity may, in part, 
account for this. It was also found that previous coinfection with CMV and EBV might 
promote protective immune surveillance to lower the risk of URTI. In addition, it can be 
concluded that athletes with low plasma vitamin D concentrations may have a higher risk of 
URTI and suffer more severe symptoms when URTI is present. This may be due to impaired 
mucosal and systemic immunity as secretory immunoglobulin A (SIgA) secretion, 
cathelicidin levels and antigen-stimulated pro-inflammatory cytokine production appear to be 
increased by vitamin D-dependent mechanisms.  
A series of follow-up studies were also conducted to examine the effect of vitamin D on 
mucosal and systemic immunity in athletes. In Chapter 4, it was reported that the influence of 
vitamin D on circulating cytokines might be different in athletes compared with non-athletes 
and that both pro-inflammatory and anti-inflammatory cytokine production by multi-antigen 
stimulated whole blood culture were not influenced by 1,25-dihydroxy vitamin D (1, 
25(OH)2D) iconcentrations within the normal healthy range. In Chapter 5, it was found that 
5000 IU of vitamin D3 supplementation daily appears to have a beneficial effect in up-
regulating the expression of SIgA and cathelicidin in athletes during a winter training period. 
Nevertheless, the findings reported in Chapter 6 showed that there were no significant effects 
of vitamin D status and a 4-week period of daily high does vitamin D3 supplementation on 
ii 
 
salivary antimicrobial protein (AMP) responses to prolonged exercise. In conclusion, a series 
of studies in this thesis have demonstrated the influence of various factors (sex differences, 
CMV/EBV serostatus and vitamin D concentrations) on susceptibility to URTI among 
athletes. Moreover, it was suggested that vitamin D3 supplementation could have a positive 
effect on immune function and lead to decreased incidence of respiratory infections. 
 
Key Words: URTI, Sex difference, Cytomegalovirus, Epstein-Barr virus, Vitamin D, Salivary 
flow rate, Antimicrobial protein 
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1.1 Exercise and upper respiratory tract illness 
URTI is the most common form of infectious illness in athletes undertaking prolonged 
intense exercise and may decrease the quality of training and hinder performance during 
competition. The relationship between exercise and susceptibility to infection has been 
modelled in the form of a 'J' shaped curve (Nieman, 1994). This model suggests that while 
engaging in moderate activity may enhance immune function above sedentary levels, 
excessive amounts of prolonged high-intensity exercise may depress immune function, 
resulting in an elevated risk of URTI. Prolonged bouts of strenuous exercise have a 
temporary negative impact on various aspects of immune function. Both aspects of innate 
immunity including neutrophil chemotaxis, phagocytosis, degranulation, and oxidative burst 
activity; and natural killer (NK) cell cytoxic activity and acquired immunity including toll-
like receptors (TLRs) expression and antigen presentation by monocytes or macrophages; T 
lymphocyte cytokine production and proliferation, immunoglobulin production by B 
lymphocytes are depressed by prolonged exercise (Gleeson & Walsh, 2012). Post-exercise 
immune function depression is most pronounced when the exercise is continuous, prolonged 
(longer than 1.5 h), of moderate to high intensity (55–75% of VO2 max), and performed 
without food intake (Gleeson, 2007). The increases in circulating stress hormones including 
adrenaline and cortisol, alterations in the pro-inflammatory and anti-inflammatory cytokine 
balance and increased free radicals are thought to cause the depression of immune function 
after prolonged exercise (Gleeson & Walsh, 2012). Furthermore, several epidemiological 
studies have showed that there is an increased incidence of URTI among highly trained 
athletes, compared with low or moderate exercising groups (Gleeson, Bishop, Oliveira, & 
Tauler, 2011; Nieman, 1994; Peters, Goetzsche, Grobbelaar, & Noakes, 1993). 
Chapter 1  Literature review 
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Figure 1.1 Factors affecting immune function from Gleeson et al. (2013) 
 
1.2 Factors influencing infection risk in athletes 
Within the general healthy human population there is a range of immuno-competency due to 
genetic differences, sex, age, nutritional status and lifestyle habits (Figure 1.1). Prolonged 
strenuous exercise has been associated with a transient depression of numerous aspects of 
immune function (Gleeson, 2006; Gleeson, 2007; Walsh et al., 2011) and a heavy schedule of 
training and competition can lead to immune impairment in athletes. This is associated with 
an apparent increased susceptibility to URTI symptoms (Fahlman & Engels, 2005; Gleeson et 
al., 1999; Heath, Macera, & Nieman, 1992; Neville, Gleeson, & Folland, 2008; Nieman, 
Johanssen, Lee, & Arabatzis, 1990; Peters & Bateman, 1983). Although several studies have 
now demonstrated a non-infectious cause of these symptoms in many cases (for example, 
airway inflammation caused by high ventilation rates or allergy) (Cox, Pyne, Saunders, 
Callister, & Gleeson, 2007; Spence et al., 2007), infectious causes of URTI appear to be 
Chapter 1  Literature review 
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mainly viral in nature. However, it is not clear what aspects of immune dysfunction are 
mostly responsible for the apparent greater incidence of infectious URTI in athletes compared 
with non-athletes. Furthermore, while it is clear that some athletes are more illness-prone 
than others, the influence of various extraneous factors (e.g. vitamin D status, prior infection 
history including CMV and EBV serostatus) on susceptibility to infection among athletes has 
not been established. 
Several risk factors have been identified for URTI in athletes including low salivary SIgA 
concentration (Gleeson et al., 1999; Neville et al., 2008) or secretion rate (Fahlman & Engels, 
2005; Gleeson et al., 2012), high anti-inflammatory cytokine response to antigen challenge 
(Gleeson et al., 2012; Gleeson, Bishop, Oliveira, & Tauler, 2011) and latent viral shedding of 
EBV (Gleeson et al., 2002). While the salivary SIgA response to acute exercise is variable, 
prolonged bouts of exercise are commonly reported to result in decreased salivary SIgA 
secretion (Bishop & Gleeson, 2009). In addition, previous studies have shown an inverse 
relationship between salivary SIgA values and URTI prevalence. For example, low salivary 
SIgA values have been reported to be associated with increased incidence of URTI in athletes 
(Fahlman & Engels, 2005; Gleeson et al., 2012; Neville et al., 2008). With regard to anti-
inflammatory cytokine response, Gleeson et al. (2013) demonstrated that the increased risk of 
URTI in individuals with high levels of physical activity might be related to an elevated anti-
inflammatory cytokine response to antigen challenge. Especially, the production of 
interleukin (IL)-10 was positively correlated with the number of weeks with URTI symptoms 
(Gleeson et al., 2012). 
Other possible factors that might predispose highly trained athletes to more frequent infection 
are sex differences, previous infection with CMV and/or EBV and low vitamin D status. The 
sex of the individual affects immune function. In females, oestrogens and progesterone 
modulate immune function (Paavonen, 1994) and thus immunity is influenced by the 
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menstrual cycle and pregnancy (Haus & Smolensky, 1999). Consequently, sex-based 
differences in responses to infection, trauma and sepsis are evident (Beery, 2003). In addition, 
another possible risk factor is previous infection with CMV and/or EBV. Both CMV and 
EBV are the members of the human herpes virus group and they persist in the body in latent 
form for a long time after primary infection and can be become reactivated when immune 
function is depressed. It has been shown that the chronic latency of both viruses has an 
influence on the immune system (Chang & Barry, 2010; Gleeson et al., 2002; Slobedman, 
Barry, Spencer, Avdic, & Abendroth, 2009). There is some new evidence that previous 
infection with CMV or EBV has a potent influence on the cellular immune responses to 
exercise (Simpson, 2011; Turner et al., 2010). Furthermore, It has only recently been 
recognised that vitamin D plays an important role in up-regulating immunity (Kamen & 
Tangpricha, 2010). Several recent studies have found an inverse association between vitamin 
D status and respiratory infection incidence in young and elderly adults (Berry, Hesketh, 
Power, & Hypponen, 2011; Ginde, Mansbach, & Camargo, 2009; Laaksi et al., 2007; Sabetta 
et al., 2010). The incidence of respiratory illnesses is generally higher in athletes (Gleeson, 
2007) and low vitamin D status could be a contributing factor as vitamin D insufficiency has 
been reported to be common in athletes (Larson-Meyer & Willis, 2010) especially if exposure 
to natural sunlight is limited. 
 
1.3 Sex differences in upper respiratory illness symptoms prevalence 
Within the general population women are generally more resistant to viral infections and tend 
to have more autoimmune diseases than men (Beery, 2003). In a review of the literature on 
respiratory tract infections (RTIs) (Falagas, Mourtzoukou, & Vardakas, 2007) in which data 
from 84 studies was extracted it was concluded that males are more susceptible than females 
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to most types of RTIs in all age groups (children, adolescents, adults and the elderly). 
Physiological, lifestyle, behavioural and socioeconomic differences between males and 
females may explain the observed findings and the involvement of sex hormones in the 
regulation of immune function may also contribute to the reported sex differences in the 
incidence and severity of the various types of RTIs, especially in adults and adolescents 
(Falagas et al., 2007). Oestrogens are generally immune enhancing, whereas progesterone 
and androgens, including testosterone, exert suppressive effects on both humoral and cellular 
immune responses. Females have higher levels of plasma immunoglobulin M (IgM) than men 
and exhibit more vigorous responses to exogenous antigens, indicating a higher level of 
humoral immunity in females than in males (Bouman, Schipper, Heineman, & Faas, 2004). In 
females, there is increased expression of some cytokines in peripheral blood and vaginal 
fluids during the follicular phase of the menstrual cycle and with use of hormonal 
contraceptives (Brabin, 2002). In the luteal phase of the menstrual cycle, blood leukocyte 
counts are higher than in the follicular phase (Faas et al., 2000), mononuclear cell expression 
of the heterodimeric transcription factor 1 (a key regulator of the innate immune response) is 
lower (Schaible, Boehringer, Callau, Niess, & Simon, 2009), and the immune response is 
shifted towards a T helper (Th) 2-type response (Faas et al., 2000). Thus, in the general 
population, there are differences in some aspects of immune function between men and 
women that appear to result in women getting fewer viral infections, including those affecting 
the respiratory tract. 
In addition to these sex differences in resting conditions, several studies have documented sex 
differences in some aspects of the immunological response to exercise (Gillum, Kuennen, 
Schneider, & Moseley, 2011; Timmons, Hamadeh, Devries, & Tarnopolsky, 2005; Timmons, 
Tarnopolsky, Snider, & Bar-Or, 2006) including larger post-exercise increases in circulating 
lymphocytes and NK cells in females. The expression of pro-inflammatory and anti-
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inflammatory genes in response to exercise is also influenced by the menstrual cycle and 
there are distinct differences in gene expression between women in the luteal phase and men 
(Northoff et al., 2008). Prolonged strenuous exercise has been associated with a transient 
depression of immune function (Gleeson, 2007; Gleeson et al., 2013; Walsh et al., 2011) and 
a heavy schedule of training and competition can lead to immune impairment in both male 
and female athletes (Walsh et al., 2011). This is associated with an increased susceptibility to 
URTI symptoms ((Fahlman & Engels, 2005; Gleeson, 2006; Gleeson et al., 1999; Heath et al., 
1992; Nieman et al., 1990; Peters & Bateman, 1983; Walsh et al., 2011) and several studies 
suggest that reduced secretion of salivary SIgA and possibly other mucosal antimicrobial 
proteins may be an important causal factor (Fahlman & Engels, 2005; Gleeson et al., 2012; 
Gleeson et al., 2013; Gleeson et al., 1999; Neville et al., 2008; Walsh et al., 2011). However, 
it is not clear whether any substantial sex differences exist in any aspect of oral-respiratory 
mucosal immune function in an athletic population or whether any such differences affect 
URTI risk. In contrast to what has been reported for the general population, some recent 
reports of illness rates among athletes attending large competitive events (e.g. winter and 
summer Olympic games, athletic and aquatic sport world championships) suggest that URTI 
episodes may actually be more prevalent in the women than the men (Alonso et al., 2012; 
Alonso et al., 2010; Edouard, Depiesse, Hertert, Branco, & Alonso, 2013; Engebretsen et al., 
2013; Engebretsen et al., 2010; Mountjoy et al., 2010; Ruedl et al., 2012). 
 
1.4 Cytomegalovirus and Epstein-Barr virus 
Both CMV and EBV, the members of the human herpes virus family of deoxyribonucleic 
acid (DNA) viruses, are predominantly associated with asymptomatic infections but may 
present as infectious mononucleosis in a proportion of cases. They persist in the body in 
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latent form for a long time after primary infection and can be become reactivated when 
immune function is depressed (Wang, Yang, Wei, Huang, & Zhao, 2010). Children and 
young adults are susceptible populations at high risk of CMV and EBV infection. While the 
majority of young children have asymptomatic CMV and EBV infections early in life in 
developing countries, the primary EBV infection is often delayed, sometimes until puberty, in 
industrialized countries (Nilsson et al., 2009). The primary CMV infections usually result 
from contact with infected body fluids, transfusion of blood products or transplantation of 
solid organs from CMV seropositive individuals (Bale, 2012). Also, primary EBV infection 
often occurs through direction contact with infected oral secretions (Savard & Gosselin, 
2006). Furthermore, EBV infection in 50-70% of cases produces symptoms of infectious 
mononucleosis characterized by fever, pharyngitis and lymphadenopathy in childhood and 
primary CMV infection might cause approximately 5-10% of cases of mononucleosis 
syndrome and will manifest symptoms almost indistinguishable from those of EBV-induced 
mononucleosis (Bale, 2012). Moreover, Bigley et al. (2012) found that a greater percentage 
of the CMV seropositive adults were EBV seropositive compared to those who were CMV 
seronegative. Thus, the coinfection with these two viruses occurs occasionally in children and 
adults as CMV and EBV have so much in common (Bigley et al., 2012; Wang et al., 2010). 
A large proportion of the adult western population has been reported to have had a previous 
infection with CMV or EBV. Bate et al. (2010) found that approximately 50% of individuals 
aged 6-49 years in the general population of the USA were CMV seropositive. Likewise, 
Lubeck et al. (2010) indicated that approximately 60% of the general population in the 
Germany had experienced a previous infection with CMV. Nevertheless, to our knowledge, 
there have been no studies examining CMV serostatus in a large number of athletes. On the 
other hand, the high proportion of previous EBV infection in general population and athletes 
has been reported in several studies. Pottgiesser et al. (2006) found that approximately 83% 
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of 200 healthy university students were EBV positive. In addition, it has been showed that 79% 
of 14 elite swimmers in Australia and 80% of 202 endurance athletes in Germany had 
previous infection with EBV (Gleeson et al., 2002; Pottgiesser et al., 2006). Given that a 
large proportion of athletes appear to have had a previous infection with CMV or EBV, it is 
important to clarify whether previous CMV or EBV infection (or both) has an important 
influence on the risk of URTI in athletes. 
 
1.5 The influence of the chronic latency of CMV and EBV on the immune system 
The successful coexistence of CMV and EBV with their hosts requires a variety of 
mechanisms of antiviral immune evasion and it has been shown that the chronic latency of 
both viruses has an influence on the immune system. Positive CMV serostatus is identified by 
the presence of IgG antibodies to CMV in plasma and although CMV does not cause overt 
symptoms of illness in itself, it can cause a general suppression of immune function via its 
production of a viral homologue of human IL-10 which might down-regulate the antigen 
presentation capacity of dendritic cells and macrophages as a strategy to limit host immune 
recognition (Chang & Barry, 2010; Slobedman et al., 2009). Thus, when immunity is 
depressed (e.g. during hard training) the latent CMV could become reactivated and might 
produce a more severe immunodepression making the individual more susceptible to 
infection. This possibility has been suggested but not yet confirmed in athletes. Likewise, 
EBV infection also produces a viral homologue of human IL-10 as a strategy to escape from 
immune detection (Slobedman et al., 2009) and could have similar effects to latent CMV 
reactivation. One small scale study with athletes has found that latent viral shedding of EBV 
in saliva during intensive training might be a factor in increasing susceptibility to other 
infections such as influenza and the common cold (Gleeson et al., 2002). 
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On the other hand, previous infection with CMV causes a substantial and sustained 
accumulation of late-differentiated effector-memory cluster of differentiation (CD)8 T cells. 
For CMV infection, it has been reported that the phenotype of virus-specific CD8 T cells 
changes over time from activated T cell in the early phase to resting vigilant effector-memory 
T cell during latency (van Leeuwen, ten Berge, & van Lier, 2007). In contrast, EBV-specific 
CD8 T cells in healthy virus carriers mostly have an early memory T-cell phenotype (Callan, 
2003). Furthermore, repeated periods of rest and reactivation from CMV or EBV latency may 
provide effective T-cell boosts and play a role in maintaining a robust and functional virus-
specific T cell population (Wherry & Ahmed, 2004). Effector-memory CD8 T cells 
possessing the ability to rapidly produce cytokines, such as interferon (IFN)- and tumour 
necrosis factor (TNF)-, are an important component of protective immunity against viral 
infections (Wherry & Ahmed, 2004). It has been reported that latent CMV infection appears 
to amplify memory CD8 T cell mobilisation and egress in response to exercise (Turner et al., 
2010). The amplification of this response may promote protective immune surveillance, and 
thereby reduce risk of infection. It could be especially protective against infection in the post-
exercise period when several other aspects of immune function are depressed. 
To our knowledge, there have been no the large-scale studies carried out to date to examine 
whether previous CMV and EBV infection modifies the incidence of URTI although it has 
been demonstrated that the chronic latency of both viruses has an influence on the immune 
system in several studies. The chronic latency of CMV and EBV might promote protective 
immune surveillance or alternatively become reactivated to produce a more severe 
immunodepression. Further research is still warranted to understand the influence of previous 
CMV or EBV infection on the risk of URTI incidence in athletes. 
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1.6 Vitamin D synthesis and metabolism 
In humans, vitamin D can be obtained either from dietary sources or the epidermal layer of 
the skin via exposure to sunlight. Two forms of vitamin D can be obtained from dietary 
sources: vitamin D3 (cholecalciferol) and vitamin D2 (ergocalciferol). While vitamin D3 is 
found in food from animal origin, such as cod-liver oil, salmon and egg yolk, vitamin D2 is 
present in some plants and fungi. The vitamin D production from ultraviolet-mediated 
conversion of 7-dehydrocholesterol in the plasma membrane of skin cells provides 80-100 % 
of body requirements (Lanteri, Lombardi, Colombini, & Banfi, 2013). This process is 
extraordinarily rapid and the production of vitamin D in the skin after only a few minutes of 
appropriate sunlight easily exceeds dietary sources. In the skin, ultraviolet radiation 
(wavelength of 290-315 nm) promotes photolytic cleavage of 7-dehydrocholesterol into pre-
vitamin D3, which is subsequently converted into vitamin D3 by a spontaneous thermal 
isomerization. Newly synthesized vitamin D and its metabolites are bound to vitamin D-
binding protein (VDBP) for systemic transport. 
Vitamin D needs to be hydroxylated twice to achieve the biologically active form, 1, 
25(OH)2D. The endogenously synthesised vitamin D3 and diet-derived D2 and D3 must first 
be hydroxylated in the liver into 25-hydroxy vitamin D, 25(OH)D, at the carbon 25-position 
by an enzyme called 25-hydroxylase. 25(OH)D is the main storage form, which can be stored 
in adipose tissue, and the major circulating metabolite of vitamin D, with a half-life of 2-3 
weeks. Therefore, the plasma concentration of 25(OH)D is considered to be the primary 
indicator of vitamin D status (Baeke, Takiishi, Korf, Gysemans, & Mathieu, 2010). Plasma 
25(OH)D values commonly accepted as the reference range are as follows (Heaney et al., 
2011; IoM, 2011). In healthy humans, 25(OH)D plasma levels >120 nmol/L are suggested as 
optimal vitamin D concentrations and levels from 50 to 120 nmol/L are defined as adequate. 
Plasma levels of 25(OH)D <50 nmol/L are proposed to define inadequate vitamin D 
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concentrations and values <30 nmol/L represent vitamin D deficiency. In the second 
hydroxylation, 25(OH)D is converted in the kidney to the biologically active form, 1, 
25(OH)2D, by 1-α-hydroxylase, an enzyme which is stimulated by parathyroid hormone 
(PTH) when serum calcium and phosphate concentrations fall below the physiological range. 
1, 25(OH)2D, is released into the circulation from the kidney which is considered as a vital 
endocrine source of hormone. Normal concentrations of circulating 1, 25(OH)2D are 
approximately 50-250 pmol/L, about 1000 times lower than its precursor, 25(OH)D; the 
plasma half-life of 1, 25(OH)2D is 4-6 hours. Some cells other than kidney, such as T cells, B 
cells, macrophages and dendritic cells, also express 1-α-hydroxylase and have the enzymatic 
machinery to convert 25(OH)D to 1, 25(OH)2D, in non-renal compartments (Aranow, 2011). 
Importantly, 1, 25(OH)2D limits its own activity in a negative feedback loop by inducing 24-
hydroxylase, which converts 1, 25(OH)2D into a biologically inactive metabolite. In addition, 
1, 25(OH)2D also inhibits the hydroxylation of renal 1-α-hydroxylase. Therefore, this 
negative feedback loop prevents excessive vitamin D activity. 
1, 25(OH)2D exerts its functions by binding to the vitamin D receptor (VDR), which is a 
nuclear receptor and ligand-activated transcription factor. The VDR is a member of the 
superfamily of nuclear hormone receptors and it is composed of an α-helical ligand-binding 
domain and a highly conserved DNA binding domain. High-affinity binding of 1, 25(OH)2D 
to the α-helical ligand-binding domain of VDR activates transcription by heterodimerization 
with the retinoid X receptor (RXR), which is essential for the high-affinity DNA binding to 
cognate vitamin D response elements (VDRE). The 1, 25(OH)2D-VDR-RXR heterodimer 
translocates to the nucleus where it binds VDRE located in the regulatory regions of 1, 
25(OH)2D target genes and then induces expression of the vitamin D responsive genes 
(Aranow, 2011).  
Chapter 1  Literature review 
13 
 
Typically, the classic function of vitamin D is to improve intestinal absorption of calcium by 
regulating several calcium transport proteins in the small intestine, and stimulating osteoclast 
differentiation to promote calcium homeostasis and bone health. However, many tissues other 
than kidney, including brain, lung, muscle, skin and adipose tissue, possess the 1-α-
hydroxylase and VDR (Baeke et al., 2010). Those cells with the 1-α-hydroxylase and VDR 
are able to produce the biologically active form of vitamin D, 1, 25(OH)2D, from circulating 
25(OH)D. It is important to note that the extra-renal 1-α-hydroxylase differs from the renal 1-
α-hydroxylase as it is not regulated by PTH, calcium and phosphate (Wu, Ren, Nguyen, 
Adams, & Hewison, 2007). Instead, the production of 1, 25(OH)2D in the extra-renal cells is 
dependent on circulating levels of 25(OH)D. 
 
1.7 Vitamin D measurements 
Measurement of plasma or serum 25(OH)D concentration is widely used in clinical practice 
and research reports to assess vitamin D status as 25(OH)D is the major circulating 
metabolite of vitamin D and seems to be “solid as a rock” in whole blood at room 
temperature. It has been demonstrated that 25(OH)D in whole blood, serum or plasma is 
stable at room temperature or when stored at -20
o
C and is unaffected by multiple freeze-thaw 
cycles (Agborsangaya et al., 2010; Antoniucci, Black, & Sellmeyer, 2005; Wielders & 
Wijnberg, 2009). Long term storage, at least three years, of serum samples at -20
o
C does not 
affect serum 25(OH)D concentrations (Agborsangaya et al., 2010). Furthermore, 25(OH)D 
concentrations in serum samples that have been thawed and refrozen up to four times are still 
reliable (Antoniucci et al., 2005). 
Plasma or serum 25(OH)D concentration can be measured by competitive protein binding 
assay, immunoassay, high pressure liquid chromatography (HPLC) and liquid 
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chromatography-tandem mass spectrometry (LC-MS/MS) (Fraser & Milan, 2013). The LC-
MS/MS method is generally considered to be the gold standard method for the measurement 
of plasma or serum 25(OH)D levels because isotope dilution LC-MS/MS method can 
simultaneously and accurately quantitate both 25(OH)D2 and 25(OH)D3 (Wallace, Gibson, de 
la Hunty, Lamberg-Allardt, & Ashwell, 2010; Zerwekh, 2008). Furthermore, both 25(OH)D2 
and 25(OH)D3 can be extracted from plasma samples using isolute C18 solid phase extraction 
cartridges in the LC-MS/MS assay. However, as the LC-MS/MS method requires expensive 
equipment, large plasma sample volume and specialised staff, the commercial enzyme-linked 
immunosorbent assays (ELISAs) are the most popular methods for measurement of plasma 
25(OH)D concentration (Fraser & Milan, 2013; Wallace et al., 2010). Current 25(OH)D 
ELISAs employ polyclonal or monoclonal antibodies that bind specifically to human 
25(OH)D. Nevertheless, the competition between the 25(OH)D specific antibodies and 
VDBP in plasma samples makes these assays difficult to control and may lead to poor 
agreement with the LC-MS/MS assay (Farrell et al., 2012; Herrmann et al., 2010). The 
plasma 25(OH)D concentration cannot be measured accurately unless it is released from 
VDBP and the strong protein binding of 25(OH)D requires the employment of suitable 
conditions to release 25(OH)D from VDBP (Fraser & Milan, 2013; Wallace et al., 2010). In 
addition, most commercial immunoassays cannot measure the concentration of 25(OH)D2 
and 25(OH)D3 independently. It has been reported that there was a underestimation of plasma 
25(OH)D2 concentration in several commercial immunoassays which resulted in marked 
variations of the total plasma 25(OH)D levels (Fraser & Milan, 2013; Wallace et al., 2010). 
Given the recent explosion of interest in vitamin D, it seems to be necessary establish which 
of the commercial ELISAs for plasma or serum 25(OH)D are the most reliable. The obvious 
potential advantages of these methods are their relative ease of use, low cost and high 
throughput using small plasma sample volumes. 
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1.8 Vitamin D status in athletes 
Recently, in a systematic literature review using the Medline and EMBASE databases 
including 195 studies conducted in 44 countries, it has been indicated that there were 37.3 % 
of the studies reporting mean plasma 25(OH)D values below 50 nmol/L (Hilger et al., 2014). 
Despite the wide number of studies that have documented a high prevalence of vitamin D 
insufficiency in the general population worldwide, there are only a handful of reports about 
the vitamin D status of athletes. A summary of the current literature on vitamin D status in 
athletes is shown in Table 1.1.  
Overall, vitamin D insufficiency has been reported to be common in athletes especially if 
exposure to natural sunlight is limited (e.g. when training in the winter months or when 
training mostly indoors). The reason for the vitamin D insufficiency in athletes might be the 
inadequate endogenous synthesis from the insufficient ultraviolet radiation (UV) exposure, 
rather than the inadequate daily vitamin D intake (Larson-Meyer & Willis, 2010). The 
vitamin D production in the skin from sufficient UV exposure provides 80-100 % of body 
requirements (Lanteri et al., 2013). Because UV radiation of appropriate wavelength needed 
to produce vitamin D in the skin is absent or drastically reduced during the winter months, 
athletes need to rely more on the diet and their stores of vitamin D that were accumulated 
during the summer months. The lack of significant amounts of vitamin D in the diet causes 
serum 25(OH)D levels to decrease precipitously and reach its nadir in the winter. In addition, 
athletes with high concentrations of melanin in their skin need up to 10 times longer UV 
exposure to produce the same amount of 25(OH)D than do fair-skinned ones as cutaneous 
melanin acts as an effective sunscreen (Hamilton et al., 2010). Therefore, athletes training in 
the winter months, training indoors, dark-skinned individuals, those who excessively use 
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high-factor sunscreen, and those living at high latitudes, are all at risk for vitamin D 
insufficiency. 
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Table 1.1 Vitamin D status in athletes 
Reference Population Location (latitude)  Number Age (years)  Season 25(OH)Vitamin D 
concentration (nmol/L) 
Bescos Garcia et 
al., 2011 
Professional basketball players Barcelona, Spain (41 ºN)  21 25 Winter 57 % < 50 
Close et al., 2013 Professional UK athletes Liverpool, UK (53°N) 61 18 - 27 Winter 62 % < 50  
Close et al., 2013 UK club athletes Liverpool, UK (53°N) 30 20 - 24 Winter 57 % < 30 
Hamilton et al., 
2010 
Middle-eastern sportsmen  Doha, Qatar (25.4 ºN) 93 13 – 45 Summer 91 % < 50 
Hamilton et al., 
2014 
Professional Qatar based footballers Doha, Qatar (25.4 ºN) 342 16 - 33 Summer 55.5 % < 50 
Lovell, 2008 Australian female gymnasts Bruce, Australia (35.3°S) 18 10 - 17 Autumn 33 % < 50 
Maroon et al., 2015 National football league players Pittsburgh, USA (40.4°N) 80 22 - 37 Winter 26 % < 50 
Morton et al., 2012 Elite soccer players  Liverpool, UK (53°N) 20 24  Winter 65 % < 50 
Storlie et al., 2011  Collegiate athletes Washington, US (46.9°N)  27 18 - 33 Autumn  3.7 % < 50  
Data are presented as mean or range. 
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1.9 Vitamin D and the immune system 
The discovery of VDR in almost all immune cells, including T lymphocytes, B lymphocytes, 
neutrophils and antigen presenting cells, such as macrophages and dendritic cells prompted 
the idea that vitamin D could have a vital role in the regulation of immune responses (Baeke 
et al., 2010). These immune cells also express the vitamin D-activating enzyme, 1-α-
hydroxylase, and thus possess the ability to convert 25(OH)D to 1, 25(OH)2D, which is 
regulated by circulating levels of 25(OH)D or induced by activation of specific toll-like TLRs 
(Bikle, 2009) which act as detectors of pathogens. Thus, 1, 25(OH)2D could play important 
roles in both innate and adaptive immune responses. 
It has been demonstrated that 1, 25(OH)2D is a vital mediator of innate immune responses, 
enhancing the antimicrobial properties of immune cells such as monocytes and macrophages 
(Bikle, 2009). 1, 25(OH)2D is a key link between TLR activation and antimicrobial responses 
in innate immunity. Following activation of the TLR signalling cascade in the presence of 
microbes, 1, 25(OH)2D has a vital role in up-regulating the production of AMPs, such as 
cathelicidin and β-defensin (Liu et al., 2006). Both macrophage and epithelial cells, 
possessing the 1-α-hydroxylase and VDR, are capable of responding to and producing 1, 
25(OH)2D. The biologically active form, 1, 25(OH)2D, could induce expression of the 
vitamin D responsive genes to enhance the production of cathelicidin and β-defensin by 
binding to VDRs (Wang et al., 2004). The stimulation of TLRs by an antimicrobial peptide in 
macrophages or by wounding the epidermis in keratinocytes results in increased expression 
of the 1-α-hydroxylase enzyme, which up-regulates the production of 1, 25(OH)2D to 
stimulate the expression of cathelicidin in the presence of adequate 25(OH)D (Liu et al., 
2006). 25(OH)D, the major circulating form used to determine vitamin D status, is an 
essential factor for the local production of 1, 25(OH)2D to up-regulate cathelicidin production 
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in the skin and in macrophages. While 1, 25(OH)2D alone is sufficient for the strong 
induction of cathelicidin expression, the combination of IL-1β and 1, 25(OH)2D is required 
for the strong induction of β-defensin. 1, 25(OH)2D can double the induction of β-defensin 
production by IL-1β signalling which stimulates the NF-κB transcription factor function (Liu 
et al., 2009). These AMPs have a broad range of activities against microorganisms and may 
be involved in the direct inactivation of viruses through membrane destabilization (Kamen & 
Tangpricha, 2010). They are produced by epithelial cells and macrophages and in the lungs 
are secreted into the biofilm covering the inner surface of the airways, thereby creating a 
barrier that is chemically lethal to microbes. In addition, 1, 25(OH)2D enhances the 
effectiveness of monocytes and macrophages in killing microbes by enhancing the generation 
of reactive oxygen species and the expression of inducible nitric oxide synthase in these 
phagocytic cells (Sly, Lopez, Nauseef, & Reiner, 2001). 
In contrast with the innate immune responses, most of the reported actions of vitamin D on 
adaptive immunity are focused on suppressive mechanisms, which could be beneficial for 
autoimmune disorders. It has been demonstrated that1, 25(OH)2D can suppress B cell 
proliferation and immunoglobulin production and inhibit the differentiation of B cell 
precursors into plasma cells, which highlights a potential role for vitamin D in B cell related 
disorders (Chen, Sims, Chen, Gu, & Lipsky, 2007). Furthermore, 1, 25(OH)2D could inhibit 
T cell proliferation and also influence the phenotype of T cells, in particular through the 
suppression of Th1 cells which are associated with cellular immunity (Lemire, Archer, Beck, 
& Spiegelberg, 1995). In contrast, 1, 25(OH)2D can enhance cytokine production by Th2 
cells which are associated with humoral immunity (Boonstra et al., 2001). Thus, vitamin D 
could help limit the tissue damage associated with excessive Th1 cellular immunity by 
shifting the balance to a Th2 cell phenotype. Recently, the impact of 1, 25(OH)2D on Th17 
cells, which are linked to inflammatory tissue damage, has been discovered. It appears that 1, 
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25(OH)2D can suppress the development of Th17 cells and inhibit the production of 
cytokines by Th17 cells (Chang, Chung, & Dong, 2010). In addition, it has been showed that 
treatment of naive CD4 T cells with 1, 25(OH)2D potently induces the development of 
regulatory T cells (Treg) which are capable of producing cytokines that block Th1 
development (Gorman et al., 2007). Overall, vitamin D acts to maintain a balance between 
inflammatory Th1/Th17 cells and immunosuppressive Th2/Treg cells to temper inflammation 
and tissue damage (Hewison, 2012).  
On the other hand, recent studies have indicated that vitamin D is essential in activating and 
controlling the T-cell antigen receptor and thus enhancing the recognition of antigens by T 
lymphocytes (Kongsbak, Levring, Geisler, & von Essen, 2013; von Essen et al., 2010) 
leading to an activation of the cellular immune response in response to pathogen exposure. 
Naive human T cells have very low expression of phospholipase C-gamma 1 (PLC-1) (a key 
signaling protein downstream of many extracellular stimuli) and this is associated with low T 
cell antigen receptor (TCR) responsiveness in naive T cells. However, TCR triggering leads 
to a large upregulation of PLC-γ1 expression, which correlates with greater TCR 
responsiveness. Induction of PLC-γ1 is dependent on vitamin D and expression of the VDR. 
Naive T cells do not express the VDR, but VDR expression is induced by TCR signaling via 
the alternative mitogen-activated protein kinase p38 pathway. Thus, initial TCR signaling via 
p38 leads to successive induction of VDR and PLC-γ1, which are required for subsequent 
classical TCR signaling and T cell activation. These findings indicate that vitamin D is 
crucial for the activation of the acquired immune system and therefore very important for the 
effective clearance of viral infections. Further studies are still warranted to understand the 
mechanism of vitamin D on adaptive immunity. 
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1.10 Vitamin D and upper respiratory tract illness 
Several recent studies have found a negative association between vitamin D status and 
respiratory infection incidence in young and elderly adults (Berry et al., 2011; Ginde et al., 
2009; Laaksi et al., 2007; Sabetta et al., 2010). In the Third National Health and Nutrition 
Examination Survey involving 18,883 participants (Ginde et al., 2009), it was found that 
individuals with plasma 25(OH)D concentration less than 25 nmol/L had a significantly 
higher risk of respiratory infections (24%) than those with 25(OH)D levels of 25-74 nmol/L 
(20%) and levels higher than 75 nmol/L (17%). Moreover, Ginde et al. (2009) demonstrated 
that an inverse association between vitamin D status and respiratory infections was present 
throughout the whole year. In addition, a population-based study on 6,789 British adults 
demonstrated that there were seasonal patterns both in plasma 25(OH)D concentrations and 
in the prevalence of URTIs, including in the winter months, that there was a 7% reduction in 
the risk of respiratory infections for each 10 nmol/L increase in plasma 25(OH)D (Berry et al., 
2011). Furthermore, a Finnish study involving 800 participants has reported that young male 
Finnish soldiers with plasma 25(OH)D concentration less than 40 nmol/L had significantly 
more days of absence from duty (median: 4 days) due to respiratory infections during the 6-
month study period than soldiers with plasma 25(OH)D concentration more than 40 nmol/L 
(median: 2 days) (Laaksi et al., 2007). Also, an observational study involving 198 healthy 
adults has shown that subjects with 25(OH)D concentrations less than 95 nmol/L had a 
significant two-fold increase in the risk of developing URTI and a longer duration of illness 
(median: 9 days) compared with those whose 25(OH)D concentrations was higher than 95 
nmol/L (median: 2 days) (Sabetta et al., 2010). Therefore, vitamin D might play an important 
role in preventing URTIs and reducing both the severity and duration of URTI symptoms. 
There are some randomised placebo-controlled and double-blind trials of vitamin D 
supplementation for the prevention of URTIs in children and adults (Aloia, Talwar, Pollack, 
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& Yeh, 2005; Camargo et al., 2012; Laaksi et al., 2010; Li-Ng et al., 2009; Murdoch et al., 
2012; Urashima et al., 2010). A 3-year randomised controlled trial with 208 healthy post-
menopausal African American women who were given 800 IU vitamin D daily or placebo for 
2 years, followed by 2000 IU vitamin D daily or placebo for one year demonstrated that there 
were less self-reported URTI symptoms in the vitamin D supplemented group compared with 
the placebo group. There were 9 reports of URTI symptoms in the vitamin D group and 30 
reports in the placebo group during the study period (Aloia et al., 2005). However, a follow-
up study by the same research group involving 162 healthy adults given 2000 IU vitamin D 
or placebo daily for 12 weeks during the winter months showed no difference in the 
incidence (vitamin D: 48 URTIs; placebo: 50 URTIs) and the duration of URTI symptoms 
(vitamin D: 5.4 days; placebo: 5.3 days) between the vitamin D group and the placebo group 
(Li-Ng et al., 2009). Nevertheless, it was noted that serum 25(OH)D levels increased 
significantly from 63.0 to 88.5 nmol/L in the intervention group after 12 weeks of vitamin D 
supplementation. In another placebo-controlled study involving 164 Finnish men who 
received vitamin D (400 IU/day) or placebo for 6 months during winter, Laaksi et al.(2010) 
found that the number of days absent from duty owing to respiratory tract infection was 
slightly lower (vitamin D: 2.2 days; placebo: 3.0 days) and the proportion of subjects without 
any days absent was significantly higher (vitamin D: 51.3 %; placebo: 35.7 %) in the vitamin 
D supplemented group compared with the control group. Furthermore, a randomised placebo-
controlled trial of daily vitamin D supplementation in 334 Japanese schoolchildren in the 
winter months demonstrated that individuals who were provided with vitamin D 
supplementation (1200 IU/day) had a significantly lower risk of type A influenza infections 
(10.8%) than those not taking any vitamin D supplement (18.6%) during the 4-month study 
period (Urashima et al., 2010). In addition, there was a vitamin D supplement study in 
Mongolian schoolchildren as well. The randomised placebo-controlled trial of daily fortified 
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milk ingestion with 300 IU of vitamin D in 247 Mongolian schoolchildren with vitamin D 
deficiency (median 25(OH)D: 17.5 nmol/L) in winter found that children receiving the 
vitamin D supplement reported significantly fewer acute respiratory infections during the 3-
month study period, compared with controls (vitamin D: 0.8; placebo: 0.4) (Camargo et al., 
2012). In contrast, Murdoch et al. (2012) conducted a high dose vitamin D supplementation 
study involving 322 healthy adults in New Zealand and reported that a monthly dose of 
100,000 IU of vitamin D in healthy adults did not significantly reduce the incidence and 
severity of URTIs during the 18-month study period. 
In conclusion, there have been mixed findings for randomised trials of vitamin D 
supplementation in the prevention of URTIs in children and adults although a negative 
association between vitamin D status and respiratory infection incidence was commonly 
presented in the observational studies. This discrepancy might be due to the varied baseline 
plasma 25(OH)D levels of participants, the different dose and duration of vitamin D 
supplementation, different populations, or the varied methods to define URTIs. Further 
studies are still warranted to investigate the preventive effect of vitamin D supplementation 
on respiratory tract infections in different populations, particularly those that may be more at 
risk of URTIs due to occupational or lifestyle stress (e.g. athletes and military personnel). 
 
1.11 Aims of thesis 
This thesis investigated the influence of various possible factors (sex differences, CMV/EBV 
serostatus and vitamin D status) on respiratory illness and immune function during a winter 
training period in athletes. Also, a series of follow-up studies were conducted to examine the 
effect of vitamin D on mucosal and systemic immunity in athletes in this thesis.  
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In Chapter 3, we conducted a study on a large cohort of endurance athletes who completed 
daily URTI symptom diaries using validated questionnaires to determine the influence of 
several possible factors on mucosal and systemic immunity as well as the incidence, severity 
and duration of URTI episodes during a winter training period. Chapter 4 describes a study 
that determined the influence of plasma 25(OH)D concentrations on circulating plasma 
cytokine concentrations in athletes and the effects of different doses of 1, 25(OH)2D3 on the 
in vitro multi-antigen stimulated cytokine production by whole blood and PBMC cultures. In 
Chapter 5, the purpose of the study was to examine the effect of vitamin D3 supplementation 
over the winter months (from December to February) on the resting plasma cathelicidin 
concentration and the salivary concentrations and secretion rates of SIgA, cathelicidin, 
lactoferrin and lysozyme in a population of individuals engaged in regular sport training. 
Chapter 6 describes a preliminary study that investigated the influence of vitamin D status 
and a short term period of daily high dose vitamin D3 supplementation on mucosal immunity 
in response to prolonged, moderate intensity exercise. 
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Several studies in this thesis required the use of similar methods. To avoid repetition, 
methods used in more than one of the experimental chapters are described in this chapter and 
will only be described in brief in the following experimental chapters. 
 
2.1 Participant recruitment 
The majority of participants were recruited from Loughborough University. Subjects were 
enrolled after having fulfilled all inclusion criteria, and presenting none of the exclusion 
criteria (determined by both questionnaire and interview). Subjects could be included if they 
were currently healthy, had been involved in endurance training for at least 2 years, engaged 
in at least 3 sessions and at least 3 h of total moderate/high-intensity training time per week 
and were between 18-40 years of age. Subjects representing one or more of the following 
criteria were excluded from participation: smoking or use of any medication, suffering from 
or had a history of cardiac, hepatic, renal, pulmonary neurological, gastrointestinal, 
haematological or psychiatric illness. 
 
2.2 Saliva and blood samples collection 
Participants came to the laboratory in the morning after an overnight fast. Subjects then sat 
quietly for 10 min before providing an unstimulated saliva sample by passive dribble into a 
pre-weighed sterile collection tube for a timed period (usually 2 min; longer was allowed if 
the volume of saliva collected after 2 min was insufficient). After centrifugation for 2 min at 
5000 g to remove cells and insoluble matter, saliva samples were stored frozen at -80ºC prior 
to analysis. Subsequently, a resting venous blood sample (12 mL) was obtained by 
venepuncture from an antecubital forearm vein into two vacutainer tubes (Becton Dickinson, 
Oxford, UK) containing K3EDTA and lithium heparin. Haematological analysis was 
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immediately carried out on the EDTA sample (including haemoglobin, haematocrit and total 
and differential leukocyte counts) using an automated cell-counter (Ac.T™5diff haematology 
analyser, Beckman Coulter, High Wycombe, UK). Subjects had to have normal haematology 
to be included in the study. The remaining EDTA blood was centrifuged for 10 min at 1500 g 
and 4ºC and the plasma stored at -80 ºC prior to analysis. Heparinised blood was used 
immediately for the measurement of antigen-stimulated cytokine production. 
 
2.3 Saliva analysis 
Saliva samples were analysed in duplicate for all the salivary AMPs. The saliva volume 
collected was estimated by weighing and the saliva flow rate was calculated. Saliva samples 
with 5X dilution were analysed for SIgA concentration using an ELISA kit (Salimetrics, 
Philadelphia, USA) and cathelicidin concentration using a commercially available ELISA kit 
(Hycult Biotech, Uden, The Netherlands). Salivary lactoferrin and lysozyme were analysed 
using commercially available ELISA kits (Calbiochem, USA and Biomedical Technologies, 
USA, respectively) with 500X dilution. Salivary HNP1-3 was analysed using commercially 
available ELISA kits (Hycult Biotech, Uden, Netherlands) with 1000X dilution. Secretion 
rates for each of the salivary AMPs were calculated as the multiple of the saliva flow rate and 
AMP concentration. All saliva assays were carried out in duplicate. The intra-assay CVs for 
all the assays were <4% across a working range of 2.5-600 mg/L for SIgA, 0.1–100 g/L for 
cathelicidin, 1.6-100 g/L for lactoferrin, 0.78-50 g/L for lysozyme and 0-10000 ng/L for 
HNP1-3. 
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2.4 Plasma analysis 
EDTA plasma was assayed for IgG antibodies to CMV and EBV using commercially 
available ELISA kits (Biocheck Inc., CA, USA and NovaTec Immunodiagnostica GmbH, 
Dietzenbach, Germany, respectively) according to the manufacturers’ instructions. The intra-
assay CVs for CMV and EBV assays were <3%. Plasma with 20X dilution was assayed in 
duplicate for cathelicidin concentration using a commercially available ELISA kit (Hycult 
Biotech, Uden, Netherlands) according to the manufacturer’s instructions. The intra-assay 
CV for cathelicidin  assay was <3% across a working range of 0.1–100 g/L. 
Vitamin D occurs in two forms: cholecalciferol (D3) which is formed by the action of UV 
light on the skin and ergocalciferol (D2) from plant food sources. The best measure of vitamin 
D concentration is considered to be the sum of the 25-hydroxy metabolites of D2 and D3 
(25(OH)D2 and 25(OH)D3) and the best way of measuring these is considered to be the LC-
MS/MS method (Wallace et al., 2010). EDTA plasma samples were analysed for 25(OH)D3 
and 25(OH)D2 with a LC-MS/MS (Waters Acuity, Manchester, UK) after a maximum of 10 
months in storage with no previous freeze-thaw cycles as described previously (Tolppanen, 
Sayers, Fraser, & Lawlor, 2012). Briefly, 25(OH)D2, 25(OH)D3 and deuterated internal 
standard were extracted from plasma samples, following protein precipitation, using Isolute 
C18 solid phase extraction cartridges. Potential interfering compounds were removed by 
initial elution with 50% methanol followed by elution of the vitamins using 10% 
tetrahydrofuran in acetonitrile. Dried extracts were reconstituted prior to injection into a high 
performance liquid chromatography tandem mass spectrometer in the multiple reaction mode 
(MRM). The MRM transitions (m/z) used were 413.2 > 395.3, 401.1 > 383.3 and 407.5 > 
107.2 for 25(OH)D2, 25(OH)D3 and hexa-deuterated(OH)D3 (internal standard), respectively. 
Intra-assay CVs were <10% across a working range of 2.5–624 nmol/L for both 25(OH)D3 
and 25(OH)D2. Measurements were performed in a laboratory meeting the performance 
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target set by the Vitamin D External Quality Assessment Scheme (DEQAS) Advisory Panel 
for 25(OH)D assays. 
 
2.5 Antigen-stimulated cytokine production 
Stimulated whole blood culture production of cytokines (IFN-, TNF-, IL-1, IL-2, IL-6 
and IL-10) was determined as described previously (Gleeson et al., 2012). The stimulant was 
a commercially available multi-antigen vaccine (Pediacel Vaccine, Sanofi Pasteur, UK) 
containing diphtheria, tetanus, acellular pertussis, poliomyelitis and haemophilus influenzae 
type b antigens. Briefly, 0.25 mL of heparinized whole blood was added to 0.75 mL of RPMI 
1640 medium (Sigma Chemicals, Poole, UK) with an added 40 µL of Pediacel vaccine 
cocktail (Sanofi Pasteur msd Limited, Maidenhead, UK) at a dilution of 1:100, before being 
incubated at 37°C and 5% CO2 for 24 h. The stimulant dilution of 1:100 used in this study 
was based on a separate experiment (unpublished data), which established the dose–response 
curve for the measured cytokines over the dilution range of 1:100–1:20 000. Samples were 
then centrifuged at 15000 rpm for 4 min at 4
o
C, following which the supernatant fluid was 
harvested and stored at -80
o
C prior to analysis of cytokine concentrations using an Evidence 
Investigator System using the high sensitivity cytokine biochip array EV3513 (Randox, 
County Antrim, UK). The intra-assay CV for all measured cytokines was less than 5.0%. 
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3.1 Abstract 
The purposes of the study were to determine the influence of possible factors, sex differences, 
CMV/EBV serostatus and vitamin D status, on mucosal and systemic immunity as well as the 
incidence, severity and duration of URTI episodes in endurance athletes during a winter 
training period. During a 4-month winter training period, we conducted a study on a large 
cohort of endurance athletes including 236 subjects (166 males, 70 females) who completed 
daily URTI symptom diaries and reported weekly training loads using validated 
questionnaires. We also collected blood samples from these athletes at the start and end of the 
study and saliva samples at the start and at 4-weekly intervals. The findings of this study 
concur with recent reports of illness incidence at major competitive games indicating that 
female athletes may be more susceptible than their male counterparts to URTI and that lower 
oral-respiratory mucosal immunity (i.e. lower secretion rates of mucosal AMPs), may 
account for this in part. Moreover, it has been indicated in the present study that athletes who 
had experienced prior infection with both CMV and EBV had fewer URTI episodes and 
fewer symptom days than those with negative serostatus for both CMV and EBV. In addition, 
our study suggested that low vitamin D status could be an important determinant of URTI 
risk in endurance athletes. Athletes with low vitamin D concentrations may have a higher risk 
of URTI and suffer more severe symptoms when URTI is present. This may be due to 
impaired mucosal and systemic immunity as salivary SIgA secretion, cathelicidin levels and 
antigen-stimulated pro-inflammatory cytokine production appear to be increased by vitamin 
D-dependent mechanisms 
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3.2 Introduction 
URTI are the most common infectious illness in athletes undertaking prolonged intense 
exercise and may decrease the quality of training and hinder performance during competition. 
The relationship between exercise and susceptibility to infection has been modelled in the 
form of a 'J' shaped curve (Nieman, 1994). This model suggests that while engaging in 
moderate activity may enhance immune function above sedentary levels, excessive amounts 
of prolonged high-intensity exercise may depress immune function, resulting in an elevated 
risk of URTI. Several epidemiological studies have showed that there is an increased 
incidence of URTI among highly trained athletes, compared with low or moderate exercising 
groups (Gleeson et al., 2013; Nieman, 1994; Peters et al., 1993). 
 
Several risk factors have been identified for URTI in athletes including low salivary SIgA 
concentration (Gleeson et al., 1999; Neville et al., 2008) or secretion rate (Fahlman & Engels, 
2005; Gleeson et al., 2012), high anti-inflammatory cytokine response to antigen challenge 
(Gleeson et al., 2012; Gleeson, Bishop, Oliveira, & Tauler, 2011) and latent viral shedding of 
EBV (Gleeson et al., 2002). Furthermore, other possible factors that might predispose highly 
trained athletes to more frequent infection are sex differences, previous infection with CMV 
and/or EBV and low vitamin D status.  
 
The sex of the individual affects immune function. In females, oestrogens and progesterone 
modulate immune function (Paavonen, 1994) and thus immunity is influenced by the 
menstrual cycle and pregnancy (Haus & Smolensky, 1999). Consequently, sex-based 
differences in responses to infection, trauma and sepsis are evident (Beery, 2003). Within the 
general population, women are generally more resistant to viral infections and tend to have 
more autoimmune diseases than men (Beery, 2003). In contrast to what has been reported for 
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the general population, some recent reports of illness rates among athletes attending large 
competitive events (e.g. winter and summer Olympic games, athletic and aquatic sport world 
championships) suggest that URTI episodes may actually be more prevalent in the women 
than the men (Alonso et al., 2012; Alonso et al., 2010; Edouard, Depiesse, Hertert, Branco, & 
Alonso, 2013; Engebretsen et al., 2013; Engebretsen et al., 2010; Mountjoy et al., 2010; 
Ruedl et al., 2012). However, it is not clear whether any substantial sex differences exist in 
any aspect of mucosal immune function in an athletic population or whether any such 
differences affect URTI risk. 
 
Both CMV and EBV are the members of the human herpes virus group and they persist in the 
body in latent form for a long time after primary infection and can be become reactivated 
when immune function is depressed. It has been shown that the chronic latency of both 
viruses has an influence on the immune system (Chang & Barry, 2010; Liu et al., 1997). 
Positive CMV serostatus (identified by the presence of IgG antibodies in plasma) is common 
among adults and although CMV does not cause overt symptoms of illness in itself, it can 
cause a general suppression of immune function via its production of a viral homologue of 
human IL-10 which is a potent inhibitory cytokine (Chang & Barry, 2010). Likewise, EBV 
infection, which in 50-70% of cases produces symptoms of infectious mononucleosis 
(glandular fever) (Niederman, Evans, Subrahmanyan, & McCollum, 1970) also produces a 
viral homologue of human IL-10 (Liu et al., 1997) and could have similar effects to CMV in 
increasing susceptibility to other infections such as influenza and the common cold. Thus, 
when immunity is depressed (e.g. during hard training) the latent CMV and/or EBV can 
become reactivated and may produce a more severe immunodepression making the individual 
more susceptible to infection. However, this possibility has been suggested but not yet 
confirmed in athletes. 
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It has only recently been recognised that vitamin D plays an important role in up-regulating 
immunity (Kamen & Tangpricha, 2010). Vitamin D is a key link between TLR activation and 
antimicrobial responses in innate immunity. Vitamin D has a vital role in up-regulating the 
expression of AMPs, such as cathelicidin and β -defensin (Liu et al., 2006). These AMPs 
have a broad range of activities against microorganisms and may be involved in the direct 
inactivation of viruses (Kamen & Tangpricha, 2010). The biologically active form of vitamin 
D, 1,25(OH)2D, activates the genes for cathelicidin synthesis and enhances the effectiveness 
of monocytes and macrophages in killing microbes by enhancing the oxidative burst potential 
of these phagocytic cells (Schwalfenberg, 2011). Furthermore, vitamin D has been shown to 
be essential in activating and controlling the T-cell antigen receptor and thus enhancing the 
recognition of antigens by T lymphocytes (von Essen et al., 2010). Vitamin D may also 
influence cytokine production during periods of infection (Cannell, Zasloff, Garland, Scragg, 
& Giovannucci, 2008). In addition, several recent studies have found a negative association 
between vitamin D status and respiratory illness incidence in young and elderly adults (Berry 
et al., 2011; Ginde et al., 2009; Laaksi et al., 2007) and the incidence of respiratory illnesses 
is generally higher in athletes (Gleeson, 2006). Therefore, low vitamin D status could be a 
contributing factor of developing URTI as vitamin D insufficiency has been reported to be 
common in athletes (Larson-Meyer & Willis, 2010) especially if exposure to natural sunlight 
is limited (e.g. when training in the winter months or when training mostly indoors).  
 
During a 4-month winter training period, we conducted a study on a large cohort of 
endurance athletes who completed daily URTI symptom diaries and reported weekly training 
loads using validated questionnaires. We also collected blood samples from these athletes at 
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the start and end of the study and saliva samples at the start and at 4-weekly intervals. The 
aims of the study were to determine the influence of possible factors, sex differences, 
CMV/EBV serostatus and vitamin D status, on mucosal and systemic immunity as well as the 
incidence, severity and duration of URTI episodes in endurance athletes during a winter 
training period. Our hypothesis was that mucosal immune variables would be lower in female 
athletes and that this might be associated with a higher prevalence of URTI episodes. We also 
hypothesized that athletes who had previous infection with CMV and/or EBV were 
predisposed to increased susceptibility to URTI. In addition, it has been hypothesized that 
athletes with low vitamin D status may have a higher risk of URTI and suffer more severe 
symptoms when URTI is present. 
 
3.3 Methods 
Subjects 
Two hundred and sixty seven subjects (184 males, 83 females) who were engaged in regular 
sports training (predominantly endurance-based activities such as running, cycling, 
swimming, triathlon, team games and racquet sports) volunteered to participate in the study. 
Subjects ranged from recreationally active to Olympic triathletes and their self-reported 
training loads averaged 10 h/week. Subjects were required to complete a comprehensive 
health-screening questionnaire prior to starting the study and had not taken any regular 
medication or antibiotics in the 3 months prior to the study. All subjects were fully informed 
about the rationale for the study and of all experimental procedures to be undertaken. 
Subjects provided written consent to participate in the study, which had earlier received the 
approval of Loughborough University ethical advisory committee. The details of inclusion 
and exclusion criteria were described in Chapter 2. 
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A total of 267 healthy individuals were recruited as subjects from Loughborough University, 
UK (latitude 53
o
N) during November 2011 with the mean age of the study cohort at 
recruitment being 21 ± 3 years (mean ± SD). For the first visit to the laboratory, subjects 
arrived in the morning at 08:30-10:30 following an overnight fast of approximately 12 h and 
their body mass and height were recorded. Information about the study was given to them and 
they then signed an informed consent form. Saliva and blood samples were collected as 
described in Chapter 2. 
 
Study protocol 
During the 4-month study period subjects were requested to continue with their normal 
training programs. Subjects completed a validated health (URTI symptoms) questionnaire 
(Jackson et al., 1958; Appendix A) on a daily basis. Subjects were not required to abstain 
from medication when they were suffering from illness symptoms but they were required, on 
a weekly basis, to report any unprescribed medications taken, visits to the doctor or any 
prescribed medications.  
 
The illness symptoms listed on the questionnaire were: sneezing, headache, malaise, nasal 
discharge, nasal obstruction, sore throat, cough, ear ache, hoarseness, fever, chilliness and 
joint aches and pains. The non-numerical severity ratings of mild, moderate and severe of 
severity of symptoms were scored as 1, 2 or 3, respectively to provide a quantitative means of 
data analysis and the total symptom score for every subject each day was calculated as a sum 
of multiplied numbers of symptoms experienced by the numerical severity ratings. A URTI 
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was deemed present when (i) total symptom score was ≥15 on any two consecutive days and 
(ii) when a subject positively indicated suffering a common cold on ≥ 3 days according to 
Jackson et al. (1958). Subjects were also asked to rate the impact of illness symptoms on their 
ability to train (above normal, at the same level, below normal or training stopped). The total 
number of URTI symptom days was also determined as the number of days with a symptom 
score of ≥5 according to Predy et al. (2005). 
 
Subjects were also asked to fill in a standard short form of IPAQ 
(http://www.ipaq.ki.se/downloads.htm) at weekly intervals, thus providing a quantitative 
information on training loads in MET-h/week (Craig et al., 2003; Appendix B). Subjects 
attended the laboratory every 4 weeks following an overnight fast. Subjects were required to 
abstain from any strenuous physical activity for 24 h before coming to the laboratory. During 
these visits body mass was recorded and an unstimulated saliva sample was collected. 
Venous blood samples were collected only at the start and end of the study period.  
 
Saliva analysis 
The saliva volume collected and flow rate were estimated as described in Chapter 2. Saliva 
samples were analysed for SIgA, α-amylase, lactoferrin and lysozyme as described in 
Chapter 2. Secretion rates for each of the salivary AMPs were calculated as described in 
Chapter 2. Values obtained from the 5 visits at 4-week intervals were averaged for each 
subject. 
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Plasma analysis 
EDTA plasma samples were assayed for IgG antibodies to CMV and EBV, cathelicidin 
concentrations and vitamin D concentrations as described in Chapter 2. 
 
Antigen-stimulated cytokine production 
Stimulated whole blood culture production of cytokines (IFN-, TNF-, IL-1, IL-2, IL-6 
and IL-10) was determined as described in Chapter 2. The analysis of cytokine concentrations 
was also described in Chapter 2. The measured cytokine concentrations for the monocyte-
derived cytokines (TNF- and IL-1) and lymphocyte-derived cytokines (IL-2 and IFN-) 
were divided by the monocyte and lymphocyte counts, respectively to give cytokine 
production per 10
6
 cells. Although the production of TNF- is divided by monocyte counts 
(the main source), it can be also produced by other cell types, such as neutrophils, NK cells 
and CD4+ T cells. IL-6 and IL-10 are produced by both monocytes and lymphocytes, so it is 
not appropriate to normalise the production of these two cytokines by cell subset counts. 
 
Statistical analysis 
The Shapiro-Wilk test was used to determine if data sets were normally distributed. Data are 
presented as mean (±SD) for data sets that were normally distributed; for data sets that were 
not normally distributed, the median and IQR are shown. The accepted level of significance 
was P<0.05.  
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The difference in proportion of subjects who presented with symptoms of infection during the 
trial between the males and females was assessed by a Chi-squared test. Self-reported training 
load (h/week), average IPAQ scores (MET-h/week), anthropometric and haematological 
variables (including blood leukocyte, neutrophil, monocyte and lymphocyte counts) were 
compared between males and females using unpaired t tests for normally distributed data. 
Changes in training load over time for both sexes were evaluated by 2-way ANOVA with 
post hoc Bonferroni t tests to locate differences from week 1. The salivary AMP 
concentrations and secretion rates were compared between males and females using 
nonparametric Mann-Whitney tests for data that were not normally distributed. The changes 
in the secretion rates of salivary AMPs over the 16 weeks of the study in males and females 
were assessed by non-parametric Friedman tests with post hoc Dunn’s tests to compare 
values at weeks 4, 8, 12 and 16 with baseline within sex. Differences between sexes at 
specific sampling timepoints were examined using Mann Whitney tests.  
 
The difference in proportion of subjects who presented with symptoms of infection during the 
trial between CMV (and EBV) positive and negative groups was compared by chi-squared 
test. Differences in mean training loads between CMV (and EBV) positive and negative 
groups were compared by independent t-test. Differences in the total number of URTI 
episodes and symptom days, the mean symptom-severity score and the mean duration of 
subjects with infection symptoms between CMV (and EBV) positive and negative serostatus 
were assessed with Mann-Whitney test. A similar analysis was applied for CMV-EBV 
combined serostatus. Mann-Whitney test was also used to examine differences in the blood 
leukocyte counts between CMV-EBV combined positive and negative serostatus. 
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The Kruskal-Wallis test (nonparametric equivalent of one-way ANOVA) with post-hoc 
Mann-Whitney test was used to examine differences in the salivary variables, blood 
leukocyte counts and  the total number of URTI episodes and symptom days among groups 
classified by vitamin D status using the following ranges for plasma total 25(OH)D: 12-30 
nmol/L (deficient); 30-50 nmol/L (inadequate),  50-120 nmol/L (adequate) and >120 nmol/L 
(suggested as optimal) (Heaney et al., 2011; IoM, 2011). For subjects with URTI symptoms, 
the symptom-severity score and the duration of URTI episodes among the 4 groups were also 
assessed using the Kruskal-Wallis test with post-hoc Mann-Whitney test. The plasma total 
25(OH)D concentrations were compared between male and female subjects, and indoor and 
outdoor training locations using the Mann-Whitney test. The total plasma 25(OH)D 
concentrations at the start and the end of the study were compared by Wilcoxon signed-rank 
test. The difference in proportion of subjects who presented with symptoms of URTI during 
the trial between the vitamin D optimal and deficient groups was assessed by the chi-squared 
test. Correlation between the number of URTI episodes and the plasma 25(OH)D 
concentration as well as the plasma cathelicidin and 25(OH)D concentration was done using 
Spearman's rank correlation coefficient. One-way ANOVA with post-hoc Bonferroni test was 
used to examine differences in the plasma cathelicidin among high, middle and low level 
vitamin D status groups. Differences in antigen-stimulated cytokine production between high 
and low vitamin D status groups were compared with the Mann-Whitney test.  
 
3.4 Results 
Adherence to the study 
Of the 267 subjects, 239 subjects completed the full 16 weeks of the study. Reasons for 
dropout included overseas travel, injury or persistent non-respiratory illness (preventing them 
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from performing training) or due to undisclosed reasons. 236 subjects (166 males, 70 females) 
provided sufficient blood for both CMV/EBV serostatus analysis and routine haematology on 
2 occasions as well as and sufficient saliva for analysis of AMPs on all 5 occasions. Among 
the females 96% reported having regular periods and 40% were taking oral contraceptives. In 
addition, plasma samples were analysed for total 25(OH)D from 225 subjects because there 
were 11 subjects having insufficient plasma volume for this analysis. At the end of the study 
blood samples with sufficient volume for analysis were obtained from 181 subjects. 
 
Baseline characteristics and physical activity levels 
The baseline characteristics between males and females are as shown in Table 3.1. There was 
no significant difference in age between males and females (Table 3.1) but males were taller, 
heavier and had higher body mass index (BMI) than females. Males had higher red blood cell 
(RBC) count, haematocrit and haemoglobin concentration than females. Total blood 
leukocyte, monocyte and lymphocyte counts were not different between the sexes but 
females had higher circulating numbers of neutrophils than males (P = 0.040). 
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Table 3.1 Anthropometric, training and haematological variables in male and female athletes 
  Males  Females  P 
Age (years)  20.4 ± 1.9  20.5 ± 3.1  0.943 
Height (cm) 1.80 ± 0.06 1.66 ± 0.06 <0.001 
Body mass (kg) 77.7 ± 10.1 63.3 ± 7.6 <0.001 
BMI (kg/m
2
) 23.8 ± 2.3 22.9 ± 2.3 0.007 
Previous training load (h/week) 10 ± 3 10 ± 3 0.857 
IPAQ (MET-h/week) 65.2 ± 28.2 66.7 ± 31.4 0.746 
RBC count (x10
12
/L) 4.86 ± 0.55 4.33 ± 0.50 <0.001 
Haematocrit (%) 46.8 ± 4.9 41.6 ± 4.6 <0.001 
Haemoglobin (g/L) 148 ± 16 130 ± 15 <0.001 
Leukocyte count (x10
9
/L) 5.85 ± 1.30 6.16 ± 1.51 0.128 
Neutrophil count (x10
9
/L) 2.96 ± 0.97 3.28 ± 1.15 0.040 
Lymphocyte count (x10
9
/L) 2.06 ± 0.52 2.05 ± 0.50 0.931 
Monocyte count (x10
9
/L) 0.58 ± 0.15 0.59 ± 0.22 0.774 
Values are expressed as mean ± SD. 
    
 
Self-reported weekly training loads (mean ± SD) based on information gathered in the pre-
screening questionnaire were similar in males and females (both 10 ± 3 h/week, P = 0.857). 
Analysis of the IPAQ questionnaires indicated that the weekly training loads were relatively 
stable within both sexes over the 16 weeks of the study (Figure 3.1) although there was a 
significant main effect of time with training load falling below week 1 values in weeks 6-11. 
There was no significant effect of sex and no significant sex x time interaction. Training 
loads were, on average, about 66 MET-h/week which is equivalent to about 11 h of 
moderate-vigorous activity per week. The training loads averaged over the whole 16-week 
study period were not significantly different between males and females (Table 3.1). 
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Figure 3.1 Training loads in MET-h/week over the 16-week study period for men (n=186) and women (n=70) 
who completed the study. Data are mean ± SD. There was a main effect of time (P<0.001) and the location of 
significant differences from week 1 are indicated as follows: * P<0.05, ** P<0.01. There was no significant 
effect of sex and no significant sex x time interaction. 
 
 
 
 
 
Infection symptom incidence and its impact on training loads 
Analysis of the URTI symptom questionnaires indicated that 4.0 ± 1.6% of the cohort 
experienced an URTI episode each week (Figure 3.2); 136 subjects did not experience a 
single URTI episode during the study period whereas 103 subjects experienced at least one 
URTI episode during the study period. The proportion of subjects whose training was 
negatively affected when URTI was present was 0.70 and when URTI was present subjects 
reduced their weekly training load by an average of 24%. 
 
Chapter 3                                      Factors influencing respiratory illness incidence in athletes 
44 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Percentage of the cohort reporting an URTI episode for each week of the study period. 
 
 
3.4.1 The effects of sex differences 
Salivary variables 
When averaged over the 5 sampling occasions, saliva flow rates and the secretion rates of 
lactoferrin, lysozyme and amylase (Table 3.2) were significantly higher in males than females. 
Concentrations of SIgA and amylase were not different between the sexes whereas lactoferrin 
(P=0.021) and lysozyme (P=0.033) concentrations were significantly higher in males. While 
there were significant effects of time for the secretion rates of lactoferrin, lysozyme, amylase 
and SIgA in males, there were significant effects of time only for amylase and SIgA secretion 
rates in females (Figure 3.3). The changes over time followed the same pattern for both sexes. 
 
URTI incidence and severity and duration of URTI 
Females tended to be more susceptible to URTI than males: The proportion of males and 
females who experienced one or more URTI episodes during the study period was 40 % of all 
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males and 52 % of all females (P=0.083, chi-squared test) and the average number of URTI 
episodes was 0.6 ± 0.8 in males and 0.8 ± 1.0 in females (P=0.103). The number of URTI 
days was significantly higher in females (males: 4.7 ± 5.0 days vs females: 6.8 ± 7.1 days, 
P=0.016). When an URTI episode was present, the mean total symptom severity score was 
not significantly different between sexes (males: 90 ± 67 vs females: 106 ± 77, P=0.312) but 
the mean duration of symptoms was significantly longer in females (males: 11.6 ± 6.8 days 
vs females: 15.5 ± 9.3 days, P=0.024). 
 
Only 17% of subjects reported that they took some medication when suffering from an URTI 
episode and only 4% reported that they visited their doctor and none were given prescription 
drugs. The study results were not corrected for this (i.e. all URTI episodes were included in 
the analysis). 
 
 
 
Table 3.2 Salivary variables in male and female athletes     
  Males  Females P 
Saliva flow rate (L/min) 340 (263-446) 308 (220-404) 0.025 
SIgA concentration (mg/L) 68.5 (49.3-97.8) 70.6 (44.8-107.9) 0.775 
SIgA secretion rate (g/min) 23.1 (13.9-34.4) 19.5 (12.2-28.8) 0.097 
Lysozyme concentration (g/L) 2000 (1112-3452) 1426 (886-2649) 0.033 
Lysozyme secretion rate (ng/min) 629 (384-1033) 373 (229-685) 0.001 
Lactoferrin concentration (g/L) 2438 (1819-3596) 1930 (1183-3365) 0.021 
Lactoferrin secretion rate (ng/min) 805 (561-1238) 554 (329-862) 0.001 
Amylase activity (U/mL) 142 (76-243) 134 (75-173) 0.126 
Amylase secretion rate (U/min) 51.6 (24.0-85.3) 37.8 (25.5-50.6) 0.009 
Values are expressed as median and interquartile range. P value is from Mann-Whitney U test. 
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Figure 3.3 Changes in salivary secretion rates over time for (A) Lactoferrin, (B) Lysozyme, (C) Amylase and (D) 
SIgA. Data are median and interquartile range. Significantly different from baseline sample within sex: † 
P<0.05, ‡ P<0.01 (Dunn’s post hoc test applied when Friedman test P<0.05). Significant difference between 
males and females at specific timepoint: * P<0.05, ** P<0.01 (Mann Whitney test). 
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Table 3.3 Illness incidence among athletes at major competitive events lasting 2-3 weeks.       
Games Season Athletes    Males Females Illness in all Illness in  Illness in  Respiratory 
    (n) (n) (n) athletes (%) males (%)  females (%) (% of total) 
Olympics 2012  Summer 10568 5892 4676 7.2 5.3 8.6 41 
Youth Olympics 2012  Winter 1021 562 459 8.4 6 11 61 
IAAF 2011 Summer 1851 971 880 6.8 7.1 7.7 39 
Olympics 2010  Winter 2567 1522 1045 7.2 5.2 8.7 63 
IAAF 2009 Summer 1979 1082 897 6.8 5.6 8.4 36 
FINA 2009 Summer 2318 1306 1012 6.6 5.1 7.9 50 
All   20304 11335 8969 7.2 ± 0.6 5.7 ± 0.8   8.7 ± 1.2*  48 ± 12 
IAAF: International Association of Athletics Federations; FINA: Federation Internationale de Natation; n = number of registered athletes.  
 * Significant difference in mean illness rates between male and female athletes (P < 0.05). 
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3.4.2 The effects of CMV/EBV serostatus 
CMV serostatus and infection incidence, severity and duration 
Twenty five percent of the subject cohort were CMV positive with a similar proportion in 
males (24%) and females (26%). There was no difference in the mean training load between 
CMV positive and negative groups (positive: 64.5 ± 29.9 MET-h/week, negative: 67.6 ± 31.1 
MET-h/week; p=0.505). There was no difference in the proportion of subjects who presented 
with symptoms of infection between CMV positive and negative groups (positive 0.38, 
negative 0.44; P=0.349). The total number of URTI symptom days in the CMV negative 
group was significantly higher than the CMV positive group (Table 3.4). There was no 
significant difference for the total number of URTI episodes and there were no significant 
differences in symptom-severity score or the duration of episodes between subjects with 
CMV positive and negative serostatus. 
 
Table 3.4 Infection symptom incidence in CMV positive and negative subjects.  
  CMV-positive CMV-negative P 
 
n = 58 n = 178 
 Number of episodes 
       Mean ± SD 0.5 ± 0.7 0.7 ± 0.9 
 Median (95 % CI) 0 (0.3-0.7) 0 (0.6-0.8) 0.107 
 
Number of symptom days 
       Mean ± SD 4.1 ± 5.4 5.8 ± 6.2 
 Median (95 % CI) 2 (2.7-5.6) 4 (4.9-6.8) 0.033 
 
n = 22 n = 80 
 Symptom-severity score 
       Mean ± SD 66.3 ± 46.0 65.2 ± 36.9 
 Median (95 % CI) 60 (45.9-86.7) 53 (56.9-73.4) 0.817 
 
Episode duration (days) 
       Mean ± SD 10.6 ± 5.7 8.6 ± 4.5 
 Median (95 % CI) 9 (8.1-13.1) 8 (7.6-9.6) 0.082 
Also shown are the severity score and duration of URTI episodes. Data are shown as mean ± SD and also as 
median and 95 % confidence intervals (CI). The P values refer to outcomes of Mann-Whitney U tests on 
nonparametric data. 
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EBV serostatus and infection incidence, severity and duration 
Eighty four percent of the subject cohort were EBV positive with a similar proportion in 
males (84%) and females (83%). There was no difference in the mean training load between 
EBV positive and negative groups (positive: 68.4 ± 31.1 MET-h/week, negative: 59.1 ± 28.3 
MET-h/week; p=0.085). There was no difference in the proportion of subjects who presented 
with symptoms of infection between EBV positive and negative groups (positive 0.41, 
negative 0.51; P=0.266). There were no significant differences for the number of URTI 
episodes, number of symptom days, the symptom-severity score or the duration of episodes 
between subjects with EBV positive and negative serostatus (Table 3.5). 
 
 
 
Table 3.5 Infection symptom incidence in EBV positive and negative subjects. 
  EBV-positive EBV-negative P 
 
n = 197 n = 39 
 Number of episodes 
       Mean ± SD 0.6 ± 0.8 0.9 ± 1.0 
 Median (95 % CI) 0 (0.5-0.7) 1 (0.5-1.2) 0.132 
 
Number of symptom days 
       Mean ± SD 5.1 ± 5.9 6.9 ± 6.8 
 Median (95 % CI) 4 (4.3-5.9) 6 (4.7-9.1) 0.133 
 
n = 82 n = 20 
 Symptom-severity score 
       Mean ± SD 65.0 ± 40.3 67.3 ± 32.9 
 Median (95 % CI) 55 (56.1-73.8) 62 (51.9-82.7) 0.404 
 
Episode duration (days) 
       Mean ± SD 9.0 ± 5.0 9.1 ± 4.4 
 Median (95 % CI) 8 (7.9-10.1) 7 (7.1-11.2) 0.859 
Also shown are the mean severity score and duration of URTI episodes.  Data are shown as mean ± SD and also 
as median and 95 % confidence intervals (CI). The P values refer to outcomes of Mann-Whitney U tests on 
nonparametric data. 
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CMV-EBV combined serostatus and infection incidence, severity and duration 
Twenty one percent of the subject cohort were both CMV and EBV positive (CMV+EBV+) 
with a similar proportion in males (19%) and females (21%), whereas 13% of the subject 
cohort had no prior CMV or EBV infection (CMV-EBV-). There was no difference in the 
mean training load between the CMV+EBV+ and CMV-EBV- groups (positive: 61.9 ± 27.8 
MET-h/week, negative: 53.5 ± 22.5 MET-h/week; P=0.161). There was no difference in the 
proportion of subjects who presented with symptoms of infection between the CMV+EBV+ 
and CMV-EBV- groups (positives 0.38, negatives 0.55; P=0.138). However, subjects with 
prior infection with both CMV and EBV had fewer URTI episodes and fewer URTI symptom 
days than subjects with no prior history of CMV and EBV infection (Table 3.6). The 
symptom-severity score and the duration of episodes were not significantly different between 
subjects in the CMV+EBV+ and CMV-EBV- groups. 
 
 
Table 3.6 Infection symptom incidence in CMV+EBV+ and CMV-EBV- subjects. 
  CMV+EBV+ CMV-EBV- P 
 
n = 50 n = 31 
 Number of episodes 
       Mean ± SD 0.5 ± 0.8 1.0 ± 1.1 
 Median (95 % CI) 0 (0.3-0.7) 1 (0.6-1.4) 0.040 
 
Number of symptom days 
       Mean ± SD 4.3 ± 5.6 7.9 ± 7.0 
 Median (95 % CI) 2 (2.7-5.9) 8 (5.3-10.4) 0.010 
 
n = 19 n = 17 
 Symptom-severity score 
       Mean ± SD 66.8 ± 49.4 68.0 ± 35.3 
 Median (95 % CI) 59 (43.0-90.6) 55 (49.8-86.1) 0.763 
 
Episode duration (days) 
       Mean ± SD 10.0 ± 5.9 8.2 ± 4.0 
 Median (95 % CI) 8 (7.2-12.9) 7 (6.2-10.3) 0.299 
Also shown are the severity score and duration of URTI episodes. Data are shown as mean ± SD and also as 
median and 95 % confidence intervals (CI). The P values refer to outcomes of Mann-Whitney U tests on 
nonparametric data. 
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Blood total and differential leukocyte counts in CMV+EBV+ and CMV-EBV- subjects 
The circulating number of lymphocytes in the CMV+EBV+ group was significantly higher 
than the CMV-EBV- group. However, there was no difference in the circulating numbers of 
total leukocytes, neutrophils or monocytes between the CMV+EBV+ and CMV-EBV- groups 
(Table 3.7).   
 
 
Table 3.7 Blood total and differential leukocyte counts in CMV+EBV+ and CMV-EBV- subjects.  
  CMV+EBV+ CMV-EBV- P 
 
n = 50 n = 31 
 Leukocytes (x10
9
 cells/L) 
       Mean ± SD 6.4 ± 1.5 5.9 ± 1.3 
 Median (95 % CI) 6.0 (5.9-6.8) 6.1 (5.4-6.3) 0.593 
 
Neutrophils (x10
9
 cells/L) 
       Mean ± SD 3.1 ± 1.2 3.0 ± 1.0 
 Median (95 % CI) 2.8 (2.8-3.5) 3.0 (2.6-3.3) 0.888 
    
Lymphocytes (x10
9
 cells/L) 
       Mean ± SD 2.4 ± 0.7 2.0 ± 0.5 
 Median (95 % CI) 2.3 (2.2-2.5) 2.0 (1.8-2.2) 0.029 
 
Monocytes (x10
9
 cells/L) 
       Mean ± SD 0.6 ± 0.2 0.6 ± 0.1 
 Median (95 % CI) 0.6 (0.6-0.7) 0.6 (0.6-0.7) 0.574 
Data are shown as mean ± SD and also as median and 95 % confidence intervals (CI). The P values refer to 
outcomes of Mann-Whitney U tests on nonparametric data. 
 
 
3.4.2 The effects of vitamin D status 
Vitamin D concentrations 
Plasma 25(OH)D2 was below the detection limit (2.5 nmol/L) in 57% of subjects and the 
average plasma 25(OH)D2 concentration was only 4.4 nmol/L (median, 0; IQR, 0-9 nmol/L) . 
The median (IQR) plasma 25(OH)D3 concentration at the start of the study was 53 (40-66) 
nmol/L and the median total 25(OH)D concentration was 57 (44-71) nmol/L. The number 
(and percentage) of subjects classed as optimal, adequate, inadequate and deficient was 11 
Chapter 3                                      Factors influencing respiratory illness incidence in athletes 
52 
 
(5%), 128 (57%), 68 (30%) and 18 (8%). Plasma 25(OH)D concentration was not 
significantly different (p=0.478) between males (N=157; median, 56; IQR, 43-69 nmol/l)  
and females (N=68; median, 58; IQR, 45-72 nmol/L). Plasma 25(OH)D concentration was 
not significantly different (P = 0.120) between indoor (N=50; median, 64; IQR, 46-73 nmol/L) 
and outdoor sports (N=175; median, 55; IQR, 43-69 nmol/L). The total plasma 25(OH)D 
concentration at the end of the study (N=181; median, 47; IQR, 35-68 nmol/L) was 
significantly lower (P=0.003) than that at the start of the study. At the start of the 4-month 
study period 38% of athletes had insufficient or deficient plasma 25(OH)D values (< 50 
nmol/L) and by the end of the study 55% of athletes had plasma 25(OH)D values of less than 
50 nmol/L. 
 
Vitamin D status and URTI incidence, severity and duration 
The proportion of subjects in the optimal vitamin D concentration group who experienced 
one or more URTI episodes during the trial was significantly lower than for the vitamin D 
deficient group (optimal 27%, deficient 67%; P=0.039). There was a significant difference 
for URTI  symptom days among the four vitamin D status groups and the total number of 
URTI  symptom days in the deficient group was significantly higher than the other groups 
(Table 4.1). Vitamin D concentration tended to influence prevalence of URTI episodes but 
this fell just short of statistical significance (P=0.061) and there was a tendency for the 
deficient group to have more episodes (Table 3.8). For subjects who experienced one or more 
URTI episodes, there was a significant difference in the median symptom-severity score per 
URTI episode among the four groups but no significant difference in the median duration of 
episodes (Table 3.8) although there was a tendency for episodes to be longer with low 
vitamin D concentration. The median symptom-severity score in the deficient group was 
significantly higher than the other groups.
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Table 3.8 Infection symptom incidence among different vitamin D status groups. Also shown are the mean severity score and duration of URTI 
episodes. 
 
  
     Optimal  Adequate  Inadequate  Deficient  P 
INCIDENCE    N = 11   N = 128  N = 68   N = 18 
 
Number of episodes   0 (0-1) * 0 (0-1)  0 (0-1)   0 (0-1)   0.062 
 
Number of symptom days  1 (0-6)*  4 (0-8)*  4 (1-8)*  9 (3-17)  0.040  
 
 
Optimal  Adequate  Inadequate  Deficient  P 
WHEN URTI PRESENT  N = 3   N = 56   N = 27   N = 12 
 
Symptom severity score  43 (38-52)*  47 (40-69)*  62 (46-74)*  102 (67-199)  0.013 
 
Duration (days)   5 (5-7)*  8 (6-9)*  8 (5-14)*   13 (10-17)  0.059 
 
 
Data are median and IQR. P value from Kruskal-Wallis test is shown in right hand column.  
* Significantly different from Deficient (Mann-Whitney U test). 
 
 
 
Chapter 3                                      Factors influencing respiratory illness incidence in athletes 
54 
 
Plasma cathelicidin concentration 
After vitamin D concentration analysis of baseline samples, we also analyzed the initial 
plasma cathelicidin concentration from a subset of 80 subjects with random selections of 
high-level (N=26; median, 111; IQR, 96-138 nmol/L), mid-level (N=27; median, 50; IQR, 
33-52 nmol/L) and low-level (N=27; median, 26; IQR, 23-28 nmol/L) 25(OH)D 
concentration. The plasma cathelicidin concentrations were 32.2 ± 11.9, 27.7±10.6 and 
24.5±7.5 ng/ml in the high, mid and low level vitamin D status groups, respectively. There 
was a significant influence of vitamin D status on the plasma cathelicidin concentration 
(P=0.027). The plasma cathelicidin concentration in the high-level vitamin D status group 
was significantly higher than in the low-level group (P=0.023). In addition, there was a 
positive correlation between the plasma 25(OH)D and cathelicidin concentrations (r = 0.234, 
P=0.036). 
 
Salivary variables 
There was a significant difference in SIgA secretion rate among the four vitamin D groups 
(Figure 3.4) but no significant difference for the other salivary AMPs (Table 3.9). The SIgA 
secretion rate in the optimal vitamin D status group was significantly higher than in the other 
groups. The SIgA concentration tended to be lowest in the deficient group. 
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Figure 3.4 Influence of vitamin D status on the saliva IgA secretion rate.  Median values for each group are 
indicated by the horizontal lines. Kruskal-Wallis test indicated a significant influence of vitamin D status on IgA 
secretion rate (P=0.018). Saliva IgA section rate was significantly higher in the Optimal group than in the other 
groups (P < 0.05). 
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Table 3.9 Salivary concentrations and secretion rates of AMPs among different vitamin D status groups.  
 
  
     Optimal  Adequate  Inadequate  Deficient  P 
     N = 11   N = 128  N = 68   N = 18 
 
Lactoferrin concentration (ng/mL) 2006 (1413-3184)       2187 (1546-3184) 2491 (1606-3633) 2419 (1624-3001) 0.948 
 
Lactoferrin SR (ng/min)  801 (587-1229) 756 (527-1151) 771 (367-1143) 872 (554-1645) 0.568  
 
Lysozyme concentration (g/mL) 1524 (641-2595)         1524 (926-2808) 1701 (1102-2693) 1361 (883-2437) 0.687 
 
Lysozyme SR (g/min)  435 (314-906)  517 (315-872)  504 (315-972)  609 (331-837)  0.970  
 
SIgA concentration (g/mL)  91 (82-130)                66 (49-100)  76 (46-11)  59 (46-78)*  0.103 
 
SIgA SR (g/min)   38.7 (30.3-48.6) 22.9 (14.2-36.6)* 19.5 (12.7-32.3)* 23.6 (14.8-32.9)* 0.018  
 
Amylase activity (U/L)  131 (60-213)               142 (73-233)  131 (74-202)  121 (64-222)  0.839 
 
 
Data are median and IQR. P value from Kruskal-Wallis test is shown in right hand column. SR = secretion rate. 
* Significantly different from Optimal (Mann-Whitney U test). 
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Blood leukocyte counts 
Based on analysis of blood samples collected at the start of the study there was no influence 
of vitamin D status on circulating numbers of total leukocytes, neutrophils, lymphocytes or 
monocytes (Table 3.10).  
 
Antigen-stimulated cytokine production 
After vitamin D concentration analysis of samples collected at the end of the study, we also 
measured antigen-stimulated cytokine production in a subset of 48 subjects with random 
selections of high-level (N=24; median, 101; IQR, 89-116 nmol/L) and low-level (N=24; 
median, 25; IQR, 20-26 nmol/L) 25(OH)D concentration (Table 3.11). Both blood monocyte 
and lymphocyte counts were not significantly different in the subset of subjects for whom 
antigen-stimulated cytokine production was determined. However, production of both 
monocyte-derived cytokines, TNF- and IL-1, were significantly lower in the low-level 
vitamin D subjects compared with those with high vitamin D status. Production of the 
lymphocyte-derived pro-inflammatory cytokine, IFN-, was significantly lower in the low-
level vitamin D subjects compared with those with high vitamin D status. Moreover, 
production of IL-6 was also significantly lower in the low-level vitamin D subjects. The 
antigen-stimulated production of IL-10 was not significantly different between the high and 
low vitamin D status groups. 
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Table 3.10 Blood total and differential leukocyte counts among different vitamin D status groups at the start of the study.  
 
  
     Optimal  Adequate  Inadequate  Deficient  P 
     N = 11   N = 128  N = 68   N = 18 
 
Leukocytes (x10
9
 cells/L)  5.9 (5.3-6.6)               5.9 (5.2-6.9)                5.9 (5.2-6.9)                6.5 (5.8-7.8)               0.495 
 
Neutrophils (x10
9
 cells/L)  2.8 (2.3-3.7)               2.9 (2.4-3.9)                3.0 (2.3-3.5)                3.4 (2.9-4.2)               0.352 
 
Lymphocytes (x10
9
 cells/L)  1.9 (1.7-2.3)               2.1 (1.7-2.3)                2.1 (1.8-2.4)                1.9 (1.8-2.0)               0.555 
 
Monocytes (x10
9
 cells/L)  0.5 (0.4-0.6)               0.6 (0.5-0.7)                0.6 (0.5-0.7)                0.6 (0.6-0.8)           0.136 
 
 
Data are median and IQR. P value from Kruskal-Wallis test is shown in right hand column.  
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Table 3.11 Antigen-stimulated cytokine production in the high and low level vitamin D groups 
  High-level (n=24) Low-level (n=24) P 
IL-6 (pg/mL) 153.6 (73.1-398.6) 50.7 (23.9-83.1) 0.012 
IL-10 (pg/mL) 4.0 (2.4-8.8) 2.8 (2.0-6.0) 0.164 
IL-2 (pg/10
6
 Ly) 21.8 (9.6-46.0) 13.4 (4.8-26.7) 0.156 
IFN- (pg/106 Ly) 9.3 (5.0-16.1) 3.8 (2.4-6.0) 0.001 
TNF- (pg/106 Mo) 34.8 (20.8-46.9) 13.7 (6.2-21.8) 0.001 
IL-1 (pg/106 Mo) 18.6 (11.3-28.0) 10.1 (6.7-13.6) 0.005 
Data are median and IQR. Ly = lymphocytes; Mo = monocytes. P value from Mann-Whitney U test is shown in right hand column. 
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3.5 Discussion 
The aims of this research were to determine the various possible factors affecting illness 
susceptibility in athletes. The main findings of the present study were that female athletes 
may be more susceptible than their male counterparts to URTI during winter training periods. 
Moreover, athletes who had experienced prior infection with both CMV and EBV may have 
fewer URTI episodes than those with negative serostatus for both CMV and EBV. In addition, 
athletes with low vitamin D status may have a higher risk of URTI and suffer more severe 
symptoms when URTI is present. 
 
3.5.1 The effects of sex differences 
Low salivary SIgA concentration or secretion rate has been identified as a risk factor for 
development of URTI in physically active individuals (Fahlman & Engels, 2005; Gleeson et 
al., 2012; Gleeson et al., 1999; Gleeson et al., 2002; Neville et al., 2008). In the present study, 
we found that female athletes tended to have lower salivary SIgA secretion rates than male 
athletes during a 16-week winter training period although this difference was not statistically 
significant. It has been suggested that salivary SIgA levels are a surrogate marker of host 
protection and the suppression of salivary SIgA after prolonged exercise or heavy training is 
itself a probable consequence of altered T lymphocyte function (Clancy et al., 2006). Females 
generally have lower unstimulated saliva flow rates than males (Percival, Challacombe, & 
Marsh, 1994), whereas SIgA concentration in unstimulated saliva has been reported to be 
unaffected by sex among relatively large cohorts of healthy young adults (Kugler, Hess, & 
Haake, 1992; van Anders, 2010; Van Anders, 2010). A previous smaller scale study reported 
lower salivary SIgA concentration and secretion rate in females (n=34) than in males (n=46) 
among a cohort of student athletes (Gleeson, Bishop, Oliveira, McCauley, & Tauler, 2011). 
Other small scale studies on elite swimmers have also reported lower SIgA concentrations in 
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females compared with males (n=11 females, n=15 males (Gleeson et al., 2012); n= 5 
females, n=7 males (Allgrove, Gomes, Hough, & Gleeson, 2008)), as has a small scale study 
of recreational cyclists (n=8 females, n=8 males (Allgrove, Geneen, Latif, & Gleeson, 2009)); 
but, to our knowledge, our investigation is the first large scale study to report a sex difference 
in salivary AMP secretion rates in athletes from a range of endurance-based sports. 
 
In the present study, it was observed that the female athletes had lower saliva amylase 
secretion rate than male athletes. Amylase, an enzyme that breaks down starch into maltose, 
is important to host defence in oral-respiratory mucosal immunity by inhibiting the adherence 
and growth of certain bacteria (Allgrove et al., 2008). The lower salivary amylase secretion 
rate in females could be at least partly due to lower circulating adrenaline levels that are 
observed both at rest (Weitz, Elam, Born, Fehm, & Dodt, 2001) and after exercise (Ruby et 
al., 1997) in females when oestrogen levels are high due to exogenous ovarian hormone 
administration. Both increased sympathetic nervous activity (Thoma, Kirschbaum, Wolf, & 
Rohleder, 2012), and elevated plasma adrenaline and noradrenaline (Chatterton, Vogelsong, 
Lu, Ellman, & Hudgens, 1996) are known to increase salivary amylase secretion. However, it 
has been indicated that sympathetic nervous activity may not be responsible for the changes 
in salivary amylase secretion (Leicht et al., 2011) and there were only 40% of females in the 
study using the oral contraceptive.  
 
In addition, we also found that the secretion rates of lysozyme and lactoferrin were 
significantly lower in female athletes than male athletes. Lysozyme and lactoferrin play 
important roles in oral-respiratory mucosal immunity against pathogen infection: Lactoferrin 
possesses the ability to sequester iron, bind to bacteria, and has antimicrobial activities that 
act in synergy with SIgA and lysozyme (Ellison, Giehl, & LaForce, 1988; Legrand, Elass, 
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Pierce, & Mazurier, 2004). Therefore, it is possible that the lower secretion rates of amylase, 
lysozyme and lactoferrin might leave female athletes at greater risk of contracting RTIs 
during winter training periods. 
 
Of course, other factors could also account for differences in infection risk between the sexes. 
For example, in the general population, women have been reported to have fewer blood 
monocytes and NK cells, but more CD4+ cells and more neutrophils than men (Bouman et al., 
2004; Willemsen, Carroll, Ring, & Drayson, 2002) and women appear to suffer from fewer 
viral infections including RTIs than men (Beery, 2003). The present study also found athletic 
females to have higher blood neutrophil counts than their male counterparts but it was the 
females who appeared to be more susceptible to URTI than men. It is possible that the same 
training load could have a greater depressive effect on humoral and systemic immunity (e.g. 
lower secretion rates of mucosal AMPs and fewer numbers of circulating B cells and NK 
cells) for women (Gleeson, Bishop, Oliveira, McCauley et al., 2011) than for men (that is not 
evident in the normal, more sedentary population) but this possibility needs to be resolved by 
future research. Such an effect may be responsible for the reversal of the usual situation of 
more effective immune function in females into the opposite situation in athletes. Our data 
support the notion that URTI are more prevalent in female athletes than their male 
counterparts when they engage in similarly high training loads. In recent years medical and 
sport science support personnel have collected data on rates of injuries and illnesses in large 
cohorts of athletes attending (and intending to compete in) large competitive events lasting 2-
3 weeks (e.g. winter and summer Olympic games, athletic and aquatic sport world 
championships). The findings from these studies are summarised in Table 2.3 and suggest 
that illness episodes actually are more prevalent in the women than the men (Alonso et al., 
2012; Alonso et al., 2010; Edouard et al., 2013; Engebretsen et al., 2013; Engebretsen et al., 
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2010; Mountjoy et al., 2010; Ruedl et al., 2012). About half of the illnesses reported at these 
events were URTI episodes. Other epidemiological studies on physically active (Nieman, 
Henson, Austin, & Sha, 2011) and athletic (Heath et al., 1991; Konig, Grathwohl, Weinstock, 
Northoff, & Berg, 2000) men and women also suggest that URTI are more prevalent in the 
females.  
 
A limitation of the present study is that the phase of the menstrual cycle (when blood and 
saliva samples were taken) was not determined but we did establish that 40% of the females 
were taking oral contraceptives. It is possible that the high training loads of some of the 
female endurance athletes in our study could have caused them to be amenorrhoeic and one 
would expect that this would make their immune variables more similar to that of men. 
However, according to the health screen questionnaire used at the start of the study 96% of 
the females reported that they had regular periods so it seems likely that during the study 
period very few of the females were amenorrhoeic. This aside, menstrual cycle phase was not 
found to affect resting saliva SIgA responses in endurance trained female athletes (Burrows, 
Bird, & Bishop, 2002). Another limitation is that we did not attempt to distinguish between 
symptoms of an infectious/illness nature vs inflammation throughout the 16 weeks of the 
study design. However, nearly all studies to date have used self-reported symptoms rather 
than pathogen identification in studies involving athletes and URTI incidence. We used the 
validated Jackson score questionnaire which is a conservative instrument requiring a 
substantial symptom score criterion threshold to define a RTI episode (Jackson et al., 1958). 
Given that the average duration of URTI episodes in our study was 13 days, it is very likely 
that the vast majority of episodes were caused by infections as typically inflammation/allergy 
symptom episodes generally only last 1-3 days according to Walsh et al. (2011). 
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The major strengths of our study are that we used a validated questionnaire (Jackson et al., 
1958) to determine URTI episodes and measured saliva AMPs on 5 occasions at monthly 
intervals to better establish the average values for each individual. The average training loads 
of the athlete cohort were generally high and were not different between males and females. 
Our study population was a group of university athletes on a single campus site so that 
environment and pathogen exposure were likely to have been similar for all subjects. 
 
3.5.2 The effects of CMV/EBV serostatus 
Contrary to our original hypothesis athletes who had previous infection with CMV or EBV 
were not predisposed to increased susceptibility to URTI. The data from our study show that 
there was no difference in the proportion of subjects who presented with symptoms of 
infection during the 4-month study period between CMV/EBV positive and negative groups. 
Although CMV or EBV can cause a general suppression of immune function via the 
production of a viral homologue of human IL-10 which is a potent inhibitory cytokine 
(Chang & Barry, 2010; Liu et al., 1997), this does not seem to be an important influence on 
URTI risk. However, a previous study has reported a significant association between prior 
infection with EBV and upper respiratory symptoms (Gleeson et al., 2002) in elite swimmers. 
Gleeson et al. (2002) indicated that while 9 of 11 EBV seropositive athletes had upper 
respiratory symptoms during a 30-day intensive training period, there were no reported upper 
respiratory symptoms in 3 EBV seronegative athletes. The reason for the different result from 
our study may be due to the relatively small numbers of athletes in their study. More 
investigations are warranted to clarify the relationship between previous CMV and EBV 
infection and the incidence of URTI. 
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In fact, we found that athletes with previous CMV infection had fewer URTI symptom days 
during the 4-month study period than those with no previous infection. Furthermore, athletes 
who had experienced prior infection with both CMV and EBV had fewer URTI episodes and 
fewer symptom days than those with negative serostatus for both CMV and EBV despite 
having similar mean training loads. The reasons for this are still unclear but could be related 
to the altered T cytotoxic cell response to exercise in individuals with positive CMV 
serostatus (Turner et al., 2010). Latent CMV infection appears to amplify memory CD8 T-
lymphocyte mobilisation and egress in response to exercise. Memory CD8 T cells possessing 
the ability to rapidly produce cytokines, such as IFN- and tumor necrosis factor alpha, are an 
important component of protective immunity against viral infections (Wherry & Ahmed, 
2004). The amplification of this response may promote protective immune surveillance, and 
thereby reduce risk of infection. It could be especially protective against infection in the post-
exercise period when several other aspects of immune function such as such as neutrophil 
oxidative burst, macrophage antigen presentation, T lymphocyte cytokine production and 
proliferation are depressed (Gleeson & Walsh, 2012). In the present study, it was also shown 
that the circulating numbers of lymphocytes at rest are significantly higher in athletes with 
CMV-EBV combined positive serostatus than those with negative serostatus which might 
also provide a higher level of immunosurveillance. Further research is still needed to 
understand the influence of previous CMV or EBV infection on the immune system. 
 
On the basis of the present data, we found that 25% of athletes had a previous CMV infection, 
84% of athletes had a previous EBV infection and 21% of athletes were both CMV and EBV 
positive. The proportion of subjects with previous CMV infection in the present study is 
lower than previously reported in the general population; Bate et al. (2010) found that 
approximately 50% individuals aged 6-49 years in the general population of the USA were 
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CMV positive and that CMV seropositivity was independently associated with older age, 
female sex, foreign birthplace and high household crowding. Nevertheless, the high 
proportion of previous EBV infection in our study is similar to other studies on young adults 
(Gleeson et al., 2002; Pottgiesser et al., 2006). Given that large proportion of athletes appear 
to have had a previous infection with CMV or EBV, it was important for further studies to 
clarify whether previous CMV or EBV infection (or both) has an important influence on the 
risk of URTI. 
 
3.5.3 The effects of vitamin D status 
According to the findings from the present study, it seems likely that vitamin D status has an 
influence on URTI symptom incidence. We found that a higher proportion of subjects (67%) 
in the vitamin D deficient status group experienced one or more URTI episodes during the 4-
month study period than in the optimal vitamin D group (27%). Recent studies have also 
shown an inverse association between vitamin D status and respiratory infection incidence in 
young and elderly adults (Berry et al., 2011; Ginde et al., 2009). In the Third National Health 
and Nutrition Examination Survey involving 18,883 participants (Ginde et al., 2009), it was 
found that individuals with plasma 25(OH)D concentration less than 25 nmol/L had a 
significantly higher risk of respiratory infections (24%) than those with 25(OH)D levels 
higher than 75 nmol/L (17%). In addition, a population-based study on 6,789 British adults 
demonstrated that plasma 25(OH)D concentrations are inversely associated with recent URTI 
(Berry et al., 2011). There was a 7% reduction in the risk of respiratory infections for each 10 
nmol/L increase in plasma 25(OH)D.  
 
Furthermore, we also found that the total number of URTI symptom days in the vitamin D 
deficient group was significantly higher than in the other groups. There was a similar result in 
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a Finnish study in which young male Finnish soldiers with plasma 25(OH)D concentration 
less than 40 nmol/L had more days of absence from duty due to respiratory infections during 
the  6-month study period  than soldiers with plasma 25(OH)D concentration more than 40 
nmol/L (Laaksi et al., 2007). In addition, an observational study has shown that  adults with 
25(OH)D status less than 95 nmol/L had a longer duration of illness compared with those 
whose 25(OH)D status was higher than 95 nmol/L (Sabetta et al., 2010). In the present study, 
it was also shown that there was a tendency for episodes to be longer with low vitamin D 
status. Moreover, we found that subjects with plasma 25(OH)D higher than 30 nmol/L had 
less severe symptoms during URTI episodes compared with those having plasma 25(OH)D 
below 30 nmol/L. Thus, vitamin D might play a role in reducing both the severity and 
duration of URTI symptoms.  
 
There is a plausible mechanism for the inverse association between plasma 25(OH)D status 
and risk/severity of URTI episodes: vitamin D is a key link between TLR activation and 
antimicrobial responses in innate immunity. Following activation of the TLR signalling 
cascade in the presence of microbes, vitamin D has a vital role in up-regulating the 
production of AMPs, such as cathelicidin and β-defensin (Liu et al., 2006). These AMPs are 
produced by both epithelial cells and macrophages and have a broad range of activities 
against microorganisms including the direct inactivation of viruses (Kamen & Tangpricha, 
2010). They are secreted into the biofilm covering the epithelial surface, thereby creating a 
barrier that is chemically lethal to microbes. One of these AMPs, cathelicidin, enhances the 
microbicidal capability of monocytes and macrophages by increasing the oxidative burst 
potential of these phagocytic cells (Schwalfenberg, 2011) and has a defined vitamin D-
dependent mechanism. Pathogenic antigens interact with TLRs on the epithelial cells and 
macrophages to upregulate the expression of the 1α-hydroxylase enzyme that converts 
Chapter 3                                      Factors influencing respiratory illness incidence in athletes 
68 
 
25(OH)D to the biologically active 1,25-dihydroxyvitamin D. This in turn activates a suite of 
genes which enhance the production of cathelicidin (Laaksi, 2012; Liu et al., 2006). Our 
finding that the plasma cathelicidin concentration in the high-level vitamin D status group 
was significantly higher than in the low-level group and the significant correlation between 
plasma 25(OH)D and cathelicidin concentrations are in agreement with other studies (Bhan et 
al., 2011; Dixon et al., 2012; Jeng et al., 2009). Furthermore, vitamin D has been shown to be 
essential in activating and controlling the T-cell antigen receptor and thus enhancing the 
recognition of antigens by T lymphocytes (von Essen et al., 2010). 
 
A novel and potentially important finding of the present study is that vitamin D deficiency 
was associated with a significant and substantially lower production of pro-inflammatory 
cytokines by both monocytes and lymphocytes in response to a multi-antigen challenge. The 
consequence of this could be an impaired immune response to an infectious pathogen, 
increasing the likelihood of an infection occurring. Our finding is in contrast to other studies 
that have indicated a reduced pro-inflammatory cytokine response when the biologically 
active form of vitamin D (1,25(OH)2D) is added in concentrations of 10-100 nmol/L to 
stimulated cultures of peripheral blood mononuclear cells (PBMC) (Khoo, Chai, Koenen, 
Kullberg et al., 2011; Khoo, Chai, Koenen, Sweep et al., 2011). The reason for this 
discrepancy is unclear. The stimulant we used was a vaccine containing antigens from a virus 
and both gram-positive and gram-negative bacteria and we used a whole blood culture. The 
studies by Khoo and colleagues (Khoo, Chai, Koenen, Kullberg et al., 2011; Khoo, Chai, 
Koenen, Sweep et al., 2011) used lipopolysaccharide (LPS) or Candida albicans to stimulate 
isolated PBMC. Inhibition of pro-inflammatory cytokine production in these studies was only 
observed when PBMC were incubated with 1,25(OH)2D in concentrations that were 50-500-
fold above the normal healthy range for plasma 1,25(OH)2D (50-250 pmol/L), so the 
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physiological relevance is questionable. Moreover, the multiple antigen challenge used in our 
study provides valuable information on cytokine production since not all cytokines respond to 
the same antigen. The capacity of leukocytes to produce cytokines upon adequate challenge 
(e.g. with mitogen, antigen, endotoxin or pathogen exposure) has potentially far reaching 
consequences for the entire functional capacity of the immune system. It is highly likely to 
reflect the capacity of an individual to defend itself against intruding microorganisms and 
hence is a suitable measure to examine the impact of nutritional interventions (e.g., vitamin D 
supplementation) designed to boost immune function. We chose to examine whole blood 
culture rather than isolated PBMC as the former retains the normal cellular, hormonal and 
cytokine milieu that the leukocytes are normally exposed to in the circulation. This model 
probably comes closest to the natural environment avoiding artefacts from cell isolation and 
preparation and allowing natural interactions between immune components and antigens 
within the normal hormonal milieu. Essentially it is an in vitro method of simulating 
responses to an infection. Our findings indicate that low vitamin D status is associated with 
an impaired ability to mount a pro-inflammatory cytokine response to a multi-antigen 
challenge, whereas the production of anti-inflammatory cytokines (IL-10) was not 
significantly influenced by vitamin D status. An impaired pro-inflammatory response to 
antigen challenge could increase the risk of succumbing to infection and increase severity 
and/or duration of symptoms of infection. 
 
Another interesting finding in the present study is that the salivary SIgA secretion rate in the 
optimal vitamin D status group was significantly higher than in the other groups. The 
mucosal immune system, especially SIgA, functions as the first line of defence against 
pathogen invasion by preventing antigens and microbes adhering to mucosal surfaces and 
interrupting replication of intracellular pathogens during transcytosis through epithelial cells 
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(Gleeson, 2007). Previous studies have shown an inverse relationship between salivary SIgA 
values and URTI prevalence. For example, low salivary SIgA values have been reported to be 
associated with increased incidence of URTI in athletes (Fahlman & Engels, 2005; Halliday 
et al., 2011; Neville et al., 2008). The finding in the present study that a significantly lower 
proportion of subjects in the vitamin D optimal status group experienced URTI episodes 
during the 4-month study period could be explained partially by the protective effect of their 
higher salivary SIgA secretion rate. To our knowledge, this is the first study to report an 
association between salivary SIgA values and plasma vitamin D status. It would be 
interesting to know if high dose Vitamin D supplementation could elevate SIgA in people 
with low SIgA secretion. 
 
The inter-individual variation in vitamin D status within our athlete cohort is most likely due 
to differences in sunlight exposure rather than diet since the D3 form (derived primarily from 
synthesis in the skin) made up >90% of total plasma 25(OH)D. None of the subjects were 
taking vitamin supplements but we did not assess dietary vitamin D intake in this study. 
Vitamin D insufficiency has been reported to be common in athletes (Larson-Meyer & Willis, 
2010) especially if exposure to natural sunlight is limited (e.g. when training in the winter 
months or when training mostly indoors). On the basis of the present data, we found that 38% 
of athletes had insufficient plasma 25(OH)D values (<50 nmol/L) at the start of the 4-month 
period and  55% of athletes had plasma 25(OH)D values of less than 50 nmol/L at the end of 
the study. This proportion is slightly lower than previously reported in a study on UK athletes 
(Close et al., 2012) that reported 61% had serum 25(OH)D concentrations of less than 50 
nmol/L during the winter months. Moreover, we also found that there was a significant drop 
in plasma 25(OH)D concentration from the start of the 4-month period to the end of the study. 
This is most likely due to insufficient UV radiation of appropriate wavelength between 
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November and March in the UK (Loughborough latitude is 53
o
N) to produce vitamin D in the 
skin (Webb & Holick, 1988). This probably also explains why there was no difference in 
plasma 25(OH)D concentration between indoor and outdoor athletes during the winter 
months in the present study, an observation also reported by other studies (Close et al., 2012; 
Halliday et al., 2011). Given that the incidence of URTI is generally higher in athletes 
(Gleeson, 2007) and that low vitamin D status could be a contributing factor, it seems 
probable that vitamin D supplementation could be desirable  for athletes during the winter 
months. Our results also provide confirmation that the presence of URTI episodes in athletes 
results in a significant reduction of their training load. 
 
3.5.4 Conclusion 
In conclusion, the findings of this study concur with recent reports of illness incidence at 
major competitive games indicating that female athletes may be more susceptible than their 
male counterparts to URTI and that lower oral-respiratory mucosal immunity (i.e. lower 
secretion rates of mucosal AMPs), may account for this in part. Moreover, it has been 
indicated in the present study that athletes who had experienced prior infection with both 
CMV and EBV had fewer URTI episodes and fewer symptom days than those with negative 
serostatus for both CMV and EBV. In addition, our study suggested that low vitamin D status 
could be an important determinant of URTI risk in endurance athletes. Athletes with low 
vitamin D concentrations may have a higher risk of URTI and suffer more severe symptoms 
when URTI is present. This may be due to impaired mucosal and systemic immunity as 
salivary SIgA secretion, cathelicidin levels and antigen-stimulated pro-inflammatory cytokine 
production appear to be increased by vitamin D-dependent mechanisms. Vitamin D seems to 
play important roles in both innate and adaptive immune responses. Therefore, a series of 
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follow-up studies were also conducted to examine the effect of vitamin D on mucosal and 
systemic immunity in athletes in this thesis. 
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Chapter 4:  
Influence of vitamin D metabolites on plasma cytokine 
concentrations in endurance sport athletes and on multi-
antigen stimulated cytokine production by whole blood 
and peripheral blood mononuclear cell cultures 
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4.1 Abstract 
Aim: Our aims were to determine the influence of plasma total 25(OH)D status on the plasma 
cytokine concentrations in athletes and the in vitro effects of different doses of 1, 25(OH)2D3 
on multi-antigen stimulated cytokine production by whole blood and PBMC cultures. 
Methods: Plasma samples from 43 athletes with high and low levels of 25(OH)D were 
assayed for the concentrations of cytokines. The whole blood samples and PBMCs from 
healthy subjects were incubated in vitro with a multi-antigen vaccine and different doses of 
added 1, 25(OH)2D3. The circulating cytokines and stimulated whole blood and PBMC 
culture production of cytokines were determined using a biochip assay. Results: The 
circulating IL-10 and IFN- concentrations were significantly higher in the vitamin D 
sufficient athletes. Furthermore, the production of TNF-, IL-6, IFN-, IL-2 and IL-10 by 
whole blood culture was significantly inhibited by 1, 25(OH)2D3 concentrations of 1000 
pmol/L or 10000 pmol/L. Conclusions: We found that the influence of vitamin D on 
circulating cytokines might be different in athletes compared with non-athletes and cytokines 
production by whole blood culture were not influenced by 1, 25(OH)2D3 in concentrations 
within the normal healthy range. 
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4.2 Introduction 
Vitamin D can be obtained either from dietary sources or the epidermal layer of the skin via 
exposure to sunlight. The endogenously synthesised vitamin D3 and diet-derived D2 and D3 
are hydroxylated in the liver to form 25(OH)D. 25(OH)D is the main storage form, which can 
be stored in muscles and adipose tissue, and is the major circulating metabolite of vitamin D, 
with a plasma half-life of 2-3 weeks. Therefore, the plasma concentration of 25(OH)D is 
considered to be the primary indicator of vitamin D status (Baeke et al., 2010). Plasma 
25(OH)D values commonly accepted as the reference range are as follows (Heaney et al., 
2011; IoM, 2011). In healthy humans, 25(OH)D plasma levels >120 nmol/L are suggested as 
optimal vitamin D status and levels from 50 to 120 nmol/L are defined as adequate. Plasma 
levels of 25(OH)D <50 nmol/L are proposed to define inadequate vitamin D concentrations 
and values <30 nmol/L represent vitamin D deficiency. Subsequently, 25(OH)D can be 
converted in the kidney to the biologically active form, 1, 25(OH)2D, by 1-α-hydroxylase, an 
enzyme which is stimulated by PTH when serum calcium and phosphate concentrations fall 
below the physiological range. Normal concentrations of circulating 1, 25(OH)2D are 
approximately 50-250 pmol/L, about 1000 times lower than its precursor, 25(OH)D; the 
plasma half-life of 1, 25(OH)2D is 4-6 hours (Aranow, 2011). 
 
It has only recently been recognised that vitamin D plays an important role in up-regulating 
immunity (Kamen & Tangpricha, 2010). Several recent studies have found a negative 
association between vitamin D status and respiratory illness incidence in young and elderly 
adults and it has been indicated that individuals with low vitamin D status have a higher risk 
of respiratory illness incidence and suffer more severe symptoms when a respiratory illness is 
present (Berry et al., 2011; Ginde et al., 2009; He et al., 2013; chapter 3). Moreover, the 
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presence of the VDR in almost all immune cells, including T lymphocytes, B lymphocytes, 
neutrophils and antigen presenting cells, such as macrophages and dendritic cells has been 
demonstrated and these immune cells also express the vitamin D-activating enzyme, 1-α-
hydroxylase, and thus possess the ability to convert 25(OH)D to 1, 25(OH)2D. This process is 
regulated by circulating levels of 25(OH)D or induced by activation of specific TLRs which 
act as detectors of pathogens (Baeke et al., 2010; Bikle, 2009). Therefore, vitamin D could 
play vital roles in both innate and adaptive immune responses. 
 
Furthermore, vitamin D may also influence circulating cytokine levels and cytokine 
production during periods of infection. Within the general population it has been reported that 
circulating pro-inflammatory cytokine concentrations, such as TNF-, IFN-, IL-1 and IL-2, 
were significantly higher in vitamin D insufficient adults compared with those who were 
vitamin D sufficient (Barker et al., 2013). However, to our knowledge, there has been no 
study to compare the difference in circulating cytokine levels between vitamin D insufficient 
and sufficient athletes. Moreover, the anti-inflammatory effects of exercise training (Gleeson, 
Bishop, Stensel et al., 2011) might modify the influence of plasma 25(OH)D on circulating 
cytokine levels in athletes. Thus, it is of interest to determine the influence of plasma 
25(OH)D status on circulating cytokine levels in athletes. In addition, several recent studies 
indicate that 1, 25(OH)2D3 limits the in vitro production of TNF-, IFN- and IL-6 by 
isolated human PBMC stimulated with LPS and Candida albicans and seasonal variations in 
vitamin D levels correlate with alterations in cytokine production by ex vivo LPS stimulated 
PBMC, with higher TNF-, IFN- and IL-6 production in winter (Khoo, Chai, Koenen, 
Kullberg et al., 2011; Khoo, Chai, Koenen, Sweep et al., 2011). Nevertheless, in our previous 
vitamin D study (He et al., 2013; chapter 3), we found that vitamin D deficiency was 
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associated with substantially lower production of pro-inflammatory cytokines, such as TNF-, 
IFN-, IL-1 and IL-6, in the whole blood culture by both monocytes and lymphocytes in 
response to a multi-antigen challenge containing antigens from viruses and both gram-
positive and gram-negative bacteria. The reason for this discrepancy is unclear and further 
research is still needed to understand the influence of vitamin D on multi-antigen stimulated 
cytokine production. 
 
In the present study, our aims were to determine the influence of plasma 25(OH)D status on 
the plasma cytokine concentrations of endurance sport athletes and the effects of different 
doses of 1, 25(OH)2D3 on the in vitro multi-antigen stimulated cytokine production by whole 
blood and PBMC cultures. 
 
4.3 Methods 
Participants 
A total of 43 healthy individuals from our previous vitamin D study (He et al., 2013; chapter 
3) were included in this study. EDTA plasma samples from athletes with high and low 
vitamin D status (high-level: 25(OH)D >80 nmol/L, n=18; low-level: 25(OH)D <40 nmol/L, 
n=25) with sufficient volume were selected for assay of the circulating cytokine 
concentrations. There was no significant difference in the physical characteristics of 
participants between high-level and low-level vitamin D status groups (Table 4.1). 
 
 
Chapter 4                                                          Influence of vitamin D metabolites on cytokines 
78 
 
 
Table 4.1 Physical characteristics of 43 athletes with high and low vitamin D status 
  high-level vitamin D low-level vitamin D P 
Number (M:F) 18 (8:10) 25 (19:6) 
 Age (years) 20.9 ± 4.1 19.9 ± 2.0 0.294 
Height (cm) 174.0 ± 10.1 177.0 ± 8.5 0.309 
Weight (kg) 71.0 ± 13.5 73.3 ± 9.4 0.516 
BMI (kg/m
2
) 23.3 ± 2.8 23.3 ± 1.8 0.960 
Mean training loads 
(Mean MET-h/wk)  
84.9 ± 46.2 64.0 ± 28.2 0.100 
Data are mean ± SD.  
  M: male; F: female. 
   P value from independent t test is shown in right hand column. 
  
 
For the study of 1, 25(OH)2D3 in vitro incubation, 6 healthy male individuals (Age: 28.8 ± 
4.1; Height: 176.3 ± 10.0; Weight: 83.9 ± 7.8; BMI: 27.1 ± 2.9) who had not taken any 
regular medication or antibiotics in the 3 months prior to the study were recruited as subjects 
from Loughborough University. For the visit to the laboratory, subjects arrived in the 
morning at 08:30-10:30 following an overnight fast of approximately 12 h. Blood samples 
were collected as described in Chapter 2. Subjects had to have normal haematology to be 
included in the study. The whole blood samples and the PBMC isolated from the heparin 
tubes were used immediately for in vitro incubation with a multi-antigen vaccine and 
different doses of 1, 25(OH)2D3. 
 
PBMC were isolated by density centrifugation on Ficoll-Hypaque Histopaque 1077 (Sigma 
Chemicals, Poole, UK). The heparinized whole blood was diluted 1:1 with room temperature 
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10 mM phosphate buffered saline (Sigma Chemicals, Poole, UK) and layered 20 mL of 
diluted blood onto 10 mL of room temperature Ficoll-Hypaque. Samples were then 
centrifuged at 800 g for 30 minutes at 20°C. Cells were collected from interphase and washed 
twice with RPMI 1640 medium (Sigma Chemicals, Poole, UK) supplemented with 10% Fetal 
Bovine Serum (Sigma Chemicals, Poole, UK) and then spun at 250 g for 10 minutes at 20°C. 
Subsequently, cells were resuspended in RPMI 1640 medium supplemented with 10% Fetal 
Bovine Serum. Cells were counted in an automated cell-counter (Ac.T™5diff haematology 
analyser, Beckman Coulter, High Wycombe, UK) and the number of cells was adjusted to 
2x10
6 
cells/mL in RPMI 1640 medium supplemented with 10% Fetal Bovine Serum. 
 
Plasma 25(OH)D measurements 
Plasma samples were assayed for 25(OH)D concentrations as described in Chapter 2. 
 
In vitro incubation with 1, 25(OH)2D3 and multi-antigen vaccine 
The whole blood samples and PBMC were incubated in vitro with a multi-antigen vaccine 
and different doses of 1, 25(OH)2D3. The stimulant was a commercially available multi-
antigen vaccine (Pediacel Vaccine, Sanofi Pasteur, UK) containing diphtheria, tetanus, 
acellular pertussis, poliomyelitis and haemophilus influenzae type b antigens. 1, 25(OH)2D3 
was purchased from Sigma-Aldrich (Missouri, USA) and dissolved in absolute ethanol to 
give a stock solution of 10 M. Aliquots were subsequently diluted with RPMI 1640 medium 
for use in the in vitro incubations. 
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Stimulated whole blood and PBMC culture production of cytokines (IFN-, TNF-, IL-1, 
IL-2, IL-6 and IL-10) were determined as described in Chapter 2. Briefly, for the 
determination of baseline unstimulated cytokine production, 0.25 mL of heparinized whole 
blood or PBMC were added to 0.75 mL of RPMI 1640 medium and incubated at 37°C and 5% 
CO2 for 24 h. Additionally, 0.25 mL of heparinized whole blood or PBMC were added to 
0.70 mL of RPMI 1640 medium containing different doses of 1, 25(OH)2D3 (0, 100, 200, 
1000 and 10000 pmol/L) with an added 50 µL of Pediacel vaccine cocktail (Sanofi Pasteur 
msd Limited, Maidenhead, UK) at a dilution of 1:100, before being incubated at 37°C and 5% 
CO2 for 24 h. The stimulant dilution of 1:100 used in this study was based on a separate 
experiment, which established the dose–response curve for the measured cytokines over the 
dilution range of 1:100–1:20,000. Samples were then centrifuged at 13000 g for 4 min at 4°C, 
following which the supernatant fluid was harvested and stored at -80°C prior to analysis of 
cytokine concentrations. 
 
Cytokine measurements 
Cytokine concentrations were determined as described in Chapter 2. The measured cytokine 
concentrations for the monocyte-derived cytokines (TNF- and IL-1) and lymphocyte-
derived cytokines (IL-2 and IFN-) were divided by the monocyte and lymphocyte counts, 
respectively to give cytokine production per 10
6
 cells. Although the production of TNF- is 
divided by monocyte counts (the main source), it can be also produced by other cell types, 
such as neutrophils, NK cells and CD4+ T cells. IL-6 and IL-10 are produced by both 
monocytes and lymphocytes, so it is not appropriate to normalise their production by cell 
subset counts. 
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Statistical analysis 
The independent t test was used to test for the differences in the physical characteristics of 
participants between high-level and low-level vitamin D groups. Mann-Whitney U test was 
used to test for the differences in the circulating cytokine concentrations between high-level 
and low-level vitamin D groups. The correlation between circulating cytokine and plasma 
25(OH)D concentrations was determined using Spearman's rank correlation. Wilcoxon 
signed rank test performed in the previous studies by Khoo and colleagues (Khoo, Chai, 
Koenen, Kullberg et al., 2011; Khoo, Chai, Koenen, Sweep et al., 2011) was also used in the 
present study to examine for the differences in the stimulated whole blood and PBMC culture 
production of cytokines between different doses of 1, 25(OH)2D3 in vitro incubation. 
Differences in the multi-antigen stimulated cytokine production without the addition of 1, 
25(OH)2D3 by whole blood and PBMC cultures were compared with the Mann-Whitney U 
test. Data are presented as mean (±SD) or median and IQR and the accepted level of 
significance was P<0.05. 
 
4.4 Results 
Circulating cytokine concentrations and vitamin D status 
The plasma 25(OH)D concentrations were 101.3±13.9 and 31.8±3.5 nmol/L in the high-level 
and low-level vitamin D status groups, respectively. The anti-inflammatory cytokine IL-10 
concentration in the high-level vitamin D status group was marginally but significantly higher 
than in the low-level group (P=0.020), and the pro-inflammatory cytokine IFN- 
concentration in the high-level vitamin D status group was substantially and significantly 
higher than in the low-level group (P=0.004) (Table 4.2). However, there was no significant 
difference in the circulating TNF-, IL-1, IL-2 and IL-6 concentrations between high-level 
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and low-level vitamin D status groups (Table 4.2). In addition, there was a positive 
correlation between the plasma 25(OH)D and IFN- concentrations (r=0.374, P=0.014), but 
plasma 25(OH)D concentrations did not correlate with TNF-, IL-1, IL-2, IL-6 or IL-10 
levels (Table 4.3). 
 
 
Table 4.2 Circulating cytokine concentrations between high-level and low-level vitamin D status groups 
  high-level vitamin D low-level vitamin D P 
IL-2 (pg/mL) 3.8 (2.6-4.5) 2.5 (0.0-5.4) 0.186 
IL-6 (pg/mL) 1.3 (1.0-1.9) 0.9 (0.7-1.5) 0.218 
IL-10 (pg/mL) 0.7 (0.6-1.6) 0.6 (0.5-0.8) 0.020 
IFN- (pg/mL) 0.9 (0.6-1.4) 0.5 (0.0-0.7) 0.004 
TNF- (pg/mL) 2.6 (1.8-3.2) 2.4 (2.0-3.3) 0.825 
IL-1 (pg/mL) 4.5 (3.3-5.7) 3.9 (2.8-7.2) 0.912 
Data are median and IQR. 
  P value from Mann-Whitney U test is shown in right hand column. 
  
 
Table 4.3 The correlation between circulating cytokine and plasma 25(OH)D concentrations 
  IL-2   IL-6 IL-10 IFN-   TNF-   IL-1   
Spearman's rank correlation 0.179 0.126 0.257 0.374 -0.157 0.006 
P value  0.250 0.421 0.097 0.014 0.314 0.970 
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Antigen-stimulated cytokine production by whole blood culture 
The antigen-stimulated production of the monocyte-derived cytokine, TNF-, was both 
attenuated by 1, 25(OH)2D3, but production of IL-1 was not significantly influenced by 1, 
25(OH)2D3. The production of TNF- was significantly lower in the presence of 1000 
pmol/L and 10000 pmol/L of 1, 25(OH)2D3 compared with its production without the 
addition of 1, 25(OH)2D3 (Figure 4.1). In addition, the antigen-stimulated production of the 
lymphocyte-derived cytokines, IFN- and IL-2, were both attenuated by 1, 25(OH)2D3. The 
production of IL-2 was significantly lower in the presence of 1000 pmol/L and 10000 pmol/L 
of 1, 25(OH)2D3 compared with its production without the addition of 1, 25(OH)2D3 and the 
production of IFN- was significantly lower in the presence of 10000 pmol/L of 1, 
25(OH)2D3 compared with its production without the addition of 1, 25(OH)2D3 (Figure 4.1). 
The production of IL-6 was significantly lower in the presence of 10000 pmol/L of 1, 
25(OH)2D3 compared with its production without the addition of 1, 25(OH)2D3 (0 pmol/L: 
201.8±202.8 pg/mL; 10000 pmol/L: 64.5±53.7 pg/mL; P=0.013), but no differences were 
observed at the other concentration of added 1, 25(OH)2D3. However, the production of IL-10 
was significantly higher in the presence of 10000 pmol/L of 1, 25(OH)2D3 compared with its 
production without the addition of 1, 25(OH)2D3 (0 pmol/L: 1.5±0.8 pg/mL; 10000 pmol/L: 
4.5±2.1 pg/mL; P=0.028), but no differences were observed at the other concentration of 
added 1, 25(OH)2D3. 
 
Antigen-stimulated cytokine production by PBMC culture 
The antigen-stimulated production of the monocyte-derived cytokines of TNF- and IL-1 
were not significantly influenced by 1, 25(OH)2D3. The antigen-stimulated production of the 
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lymphocyte-derived cytokines, IFN- and IL-2, were not significantly influenced by the 
incubation of different doses of 1, 25(OH)2D3 (Figure 4.2). The production of IL-10 was also 
not significantly influenced by 1, 25(OH)2D3. However, the production of IL-6 was 
significantly lower in the presence of 10000 pmol/L of 1, 25(OH)2D3 compared with its 
production without the addition of 1, 25(OH)2D3 (0 pmol/L: 199.2±100.8 pg/mL; 10000 
pmol/L: 81.1±34.4 pg/mL; P = 0.038). 
 
Comparison of the whole blood and PBMC culture 
The production of the lymphocyte-derived cytokines, IFN- and IL-2, and the monocyte-
derived cytokine, IL-1, by multi-antigen stimulated whole blood culture without the 
addition of 1, 25(OH)2D3 were significantly higher than their respective production by the 
PBMC culture (Table 4.4). However, there was no significant difference in the antigen-
stimulated production of TNF-, IL-6 and IL-10 between the whole blood and PBMC 
cultures (Table 4.4). 
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Table 4.4 Comparison of the whole blood and PBMC culture in antigen-stimulated cytokine production 
  whole blood PBMC P 
IL-6 (pg/mL) 195.7 (65.9-245.3) 161.5 (156.1-202.1) 0.262 
IL-10 (pg/mL) 1.7 (1.5-1.8) 2.0 (1.6-2.3) 0.297 
IL-2 (pg/10
6
 Ly) 9.5 (4.5-16.6) 0.3 (0.2-0.7) 0.016 
IFN- (pg/106 Ly) 0.6 (0.3-0.9) 0.1 (0.0-0.1) 0.037 
TNF- (pg/106 Mo) 8.4 (3.6-11.9) 7.7 (6.4-11.7) 0.631 
IL-1 (pg/106 Mo) 6.4 (4.3-8.8) 1.6 (1.3-2.6) 0.037 
Data are median and IQR.  
Ly = lymphocytes; Mo = monocytes 
  P value from Mann-Whitney U test is shown in right hand column. 
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Figure 4.1 The antigen-stimulated production of the lymphocyte-derived cytokines (IL-2 and IFN-; left panels) 
and the monocyte-derived cytokines (TNF- and IL-1; right panels) by whole blood culture. *P<0.05 vs 0 
pmol/L. Ly = lymphocytes; Mo = monocytes. Data are presented as mean and SD. 
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Figure 4.2 The antigen-stimulated production of the lymphocyte-derived cytokines (IL-2 and IFN-; left panels) 
and the monocyte-derived cytokines (TNF- and IL-1; right panels) by PBMC culture. *P<0.05 vs 0 pmol/L. 
Ly = lymphocytes; Mo = monocytes. Data are presented as mean and SD. 
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4.5 Discussion 
The aims of this research were to determine the influence of plasma 25(OH)D status on the 
circulating cytokine levels in endurance sport athletes and the effects of different doses of 1, 
25(OH)2D3 on the multi-antigen stimulated cytokine production by whole blood and PBMC 
cultures. The main findings of the present study were that the circulating IL-10 and IFN- 
concentrations were significantly higher in the vitamin D sufficient athletes compared with 
the vitamin D insufficient athletes and there was a positive correlation between the plasma 
25(OH)D and IFN- concentrations in endurance athletes. Furthermore, the production of 
TNF-, IL-6, IFN-, IL-2 and IL-10 by multi-antigen stimulated whole blood culture were 
significantly influenced by 1, 25(OH)2D3 of concentrations of 1000 pmol/L and/or 10000 
pmol/L. Nevertheless, a similar effect was only observed for the production of IL-6 by multi-
antigen stimulated PBMC culture. In addition, the production of lymphocyte-derived and 
monocyte-derived cytokines, such as IFN-, IL-2 and IL-1, were significantly different in 
the multi-antigen stimulated whole blood culture without the addition of 1, 25(OH)2D3 
compared with its production in the PBMC culture. 
 
On the basis of the present data, we found that the circulating IL-10 and IFN- concentrations 
in the vitamin D sufficient athletes were significantly higher than in the vitamin D 
insufficient athletes and there was a positive correlation between the plasma 25(OH)D and 
IFN- concentrations in endurance athletes. In contrast, a previous study has reported an 
elevation of circulating pro-inflammatory cytokines in vitamin D insufficient adults (Barker 
et al., 2013). Barker et al. (2013) indicated that circulating pro-inflammatory cytokine 
concentrations, such as TNF-, IFN-, IL-1 and IL-2, were significantly higher in vitamin D 
insufficient compared to vitamin D sufficient adults but the anti-inflammatory cytokine, IL-
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10, was not significantly different between vitamin D insufficient and sufficient adults. 
Moreover, Barker and colleagues (Barker, Martins, Kjeldsberg, Trawick, & Hill, 2012) found 
an inverse correlation between the plasma 25(OH)D and IFN- concentrations. The reason for 
this discrepancy is still unclear but may be due to the difference of the cut-off point used for 
vitamin D insufficiency in the two studies. In healthy humans, 25(OH)D plasma levels >120 
nmol/L are suggested as optimal vitamin D status and levels from 50 to 120 nmol/L are 
defined as adequate. Plasma levels of 25(OH)D <50 nmol/L are proposed to define 
inadequate vitamin D concentrations and values <30 nmol/L represent vitamin D deficiency 
(Heaney et al., 2011; IoM, 2011). Therefore, the commonly used cut-off point for vitamin D 
insufficiency in clinical practice and research reports is the threshold concentration of 
25(OH)D of <50 nmol/L (Lai, Lucas, Banks, & Ponsonby, 2012). However, the cut-off point 
for vitamin D insufficiency used in the Barker et al. (2013) study was <80 nmol/L and the 
average serum 25(OH)D concentration of vitamin D of insufficient adults was around 60 
nmol/L. Thus, the vitamin D insufficient adults in their study were not even close to being 
vitamin D deficient. In addition, another confounding factor may be due to the anti-
inflammatory effects of exercise training. The participants recruited in our previous vitamin 
D study (He et al., 2013; chapter 3) were the endurance sport athletes engaged in regular 
sports training (predominantly endurance-based activities such as running, cycling, 
swimming, triathlon, team games and racquet sports) and their self-reported training loads 
averaged 10 h/week. The anti-inflammatory effects of exercise training on cytokine responses, 
such as the release of IL-6 from contracting muscle and the increased levels of circulating IL-
10, cortisol and adrenaline, are discussed in the review article by (Gleeson, Bishop, Stensel et 
al., 2011). It has been demonstrated that the active skeletal muscle significantly increases 
both cellular and circulating levels of IL-6 during and following exercise of sufficient load 
and the transient rise in circulating IL-6 during exercise appears to be responsible for a 
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subsequent rise in circulating levels of anti-inflammatory cytokines, including IL-10, which 
is a potent promoter of an anti-inflammatory state (Gleeson, Bishop, Stensel et al., 2011). 
Increases in circulating cortisol and adrenaline during exercise are due to activation of the 
hypothalamic–pituitary–adrenal axis and the sympathetic nervous system, respectively. 
Cortisol is known to have potent anti-inflammatory effects and also augmented by the rise in 
circulating IL-6 from contracting skeletal muscle (Gleeson, Bishop, Stensel et al., 2011). 
Therefore, the influence of vitamin D on circulating cytokines might be different between 
athletes and non-athletes. Further research is still needed to understand the influence of 
vitamin D on circulating cytokines between athletes and non-athletes. 
 
The finding of higher circulating IFN- concentrations in the vitamin D sufficient athletes and 
a positive correlation between the plasma 25(OH)D and IFN- concentrations in the present 
study might be helpful to support the arguments that vitamin D could play a role in reducing 
both the severity and duration of upper respiratory tract illness symptoms in our previous 
vitamin D study (He et al., 2013; chapter 3). It has been reported that increasing IFN- in the 
circulation contributes to the conversion of 25(OH)D to its active hormonal form, 1, 
25(OH)2D, in the circulation during inflammatory stress in humans (Barker et al., 2012). In 
addition, 1, 25(OH)2D has a vital role in up-regulating the production of antimicrobial 
proteins and peptides, such as cathelicidin and β-defensin, which are produced by both 
epithelial cells and macrophages and have a broad range of activities against microorganisms 
including the direct inactivation of viruses (Liu et al., 2006). 1, 25(OH)2D also acts to 
maintain a balance between inflammatory Th1/Th17 cells and immunosuppressive Th2/Treg 
cells to temper inflammation and tissue damage (Hewison, 2012). Therefore, the vitamin D 
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sufficient athletes with higher circulating IFN- concentrations may have less severe 
symptoms and shorter duration when the upper respiratory tract illness is present. 
 
According to the findings from the present study, it seems likely that the multi-antigen 
stimulated cytokine production by whole blood culture was influenced by 1, 25(OH)2D3 only 
in concentrations that were 1000 pmol/L or more. Although the production of pro-
inflammatory cytokines, TNF-, IL-6, IFN- and IL-2 by multi-antigen stimulated whole 
blood culture were significantly lower in the presence of 1000 pmol/L or 10000 pmol/L of 1, 
25(OH)2D3 and the production of anti-inflammatory cytokine, IL-10, was significantly higher 
in the presence of 10000 pmol/L of 1, 25(OH)2D3, we found that both pro-inflammatory and 
anti-inflammatory cytokine production by multi-antigen stimulated whole blood culture were 
not influenced by 1, 25(OH)2D3 in added concentrations of 100 pmol/L and 200 pmol/L. In 
contrast, the results from our previous study (He et al., 2013; chapter 3) showed that vitamin 
D status (determined by plasma levels of 25(OH)D) did significantly influence lymphocyte 
and monocyte pro-inflammatory cytokine production by antigen-stimulated whole blood 
culture. Individuals with high levels of plasma 25(OH)D would be expected to have higher 
levels of 1, 25(OH)2D so it is perhaps surprising that in the in vitro situation variations in 1, 
25(OH)2D within the normal physiological range appear to have no significant effect on 
leukocyte cytokine production. In healthy humans, normal concentrations of circulating 1, 
25(OH)2D are approximately 50-250 pmol/L, about 1000 times lower than its precursor, 
25(OH)D (Aranow, 2011). Inhibition of pro-inflammatory cytokine production and elevation 
of anti-inflammatory cytokine production in the present study were only observed when the 
whole blood was incubated with 1, 25(OH)2D in concentrations that were 10-100-fold above 
the normal healthy range for plasma 1, 25(OH)2D. Therefore, the physiological relevance is 
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unclear. A limitation of the present study is that the participants’ plasma concentration of 1, 
25(OH)2D was not determined. Further research is still needed to understand the influence of 
the normal healthy range or lower levels of plasma 1, 25(OH)2D on the multi-antigen 
stimulated cytokine production by whole blood culture. 
 
The data from our study show that there was a significant difference in the production of 
multi-antigen stimulated lymphocyte-derived and monocyte-derived cytokines, such as IFN-, 
IL-2, IL-4 and IL-1, between the whole blood and PBMC cultures and it seems likely that 
there was a better dose-dependent response in the cytokine production of multi-antigen 
stimulated whole blood culture with different doses of 1, 25(OH)2D3 than in the PBMC 
culture. The whole blood culture retains the normal cellular, hormonal and cytokine milieu 
that the leukocytes are normally exposed to in the circulation. This model probably comes 
closest to the natural environment avoiding artefacts from cell isolation and preparation and 
allowing natural interactions between immune components and antigens within the normal 
hormonal milieu. Essentially it is an in vitro method of simulating responses to an infection. 
Moreover, the stimulant we used was a vaccine containing antigens from a virus and both 
gram-positive and gram-negative bacteria and the multiple antigen challenge used in the 
present study provides valuable information on cytokine production since not all cytokines 
respond to the same antigen. The capacity of leukocytes to produce cytokines upon adequate 
challenge (e.g. with mitogen, antigen, endotoxin or pathogen exposure) has potentially far 
reaching consequences for the entire functional capacity of the immune system. Therefore, 
the whole blood culture stimulated with multi-antigen is highly likely to reflect the capacity 
of an individual to defend itself against intruding microorganisms. 
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In conclusion, the present study demonstrated that the influence of vitamin D on circulating 
cytokines might be different in athletes compared with previous studies on non-athletes and 
the higher circulating IFN- concentrations in vitamin D sufficient athletes might be helpful 
to support the arguments that vitamin D could play a role in reducing both the severity and 
duration of upper respiratory tract illness symptoms. In addition, we found that both pro-
inflammatory and anti-inflammatory cytokines by multi-antigen stimulated whole blood 
culture were not influenced by 1, 25(OH)2D3 in concentrations within the normal healthy 
range. Furthermore, the whole blood culture stimulated with multi-antigen might be a better 
in vitro method of simulating responses to an infection than cultures using PBMCs. 
 
  
Chapter 5                                                                     14 weeks of vitamin D3 supplementation 
94 
 
 
 
 
 
 
 
 
 
Chapter 5:  
The effect of 14 weeks of vitamin D3 supplementation on 
antimicrobial peptides and proteins in athletes 
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5.1 Abstract 
Heavy training is associated with increased respiratory infection risk and antimicrobial 
proteins are important in defence against oral and respiratory tract infections. We examined 
the effect of vitamin D3 supplementation (5000 IU/day) during the winter months on the 
resting plasma cathelicidin concentration and the salivary secretion rates of SIgA, cathelicidin, 
lactoferrin and lysozyme in athletes during a winter training period. Blood and saliva were 
obtained at the start of the study from 39 healthy men who were randomly allocated to 
vitamin D3 supplement or placebo. Blood samples were also collected at the end of the study; 
saliva samples were collected after 7 and 14 weeks. Plasma total 25(OH)D concentration 
increased by 130% in the vitamin D3 group and decreased by 43% in the placebo group (both 
P=0.001). The percentage change of plasma cathelicidin concentration in the vitamin D3 
group was higher than in the placebo group (P=0.025). Only in the vitamin D3 group, the 
saliva SIgA and cathelicidin secretion rates increased over time (both P=0.03). A daily 5000 
IU vitamin D3 supplement has a beneficial effect in up-regulating the expression of SIgA and 
cathelicidin in athletes during a winter training period which could improve resistance to 
respiratory infections.  
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5.2 Introduction  
Vitamin D can be obtained either from dietary sources or the epidermal layer of the skin via 
exposure to sunlight. Two forms of vitamin D can be obtained from dietary sources: vitamin 
D3 (cholecalciferol) and vitamin D2 (ergocalciferol). While vitamin D3 is found in food from 
animal origin, such as cod-liver oil, salmon and egg yolk, vitamin D2 is present in some 
plants and fungi. The vitamin D3 production from ultraviolet-mediated conversion of 7-
dehydrocholesterol in the plasma membrane of skin cells provides 80-100 % of the body’s 
requirements (Lanteri et al., 2013). The endogenously synthesised vitamin D3 and diet-
derived D2 and D3 must first be hydroxylated in the liver into 25(OH)D, the main storage 
form. In the second hydroxylation, 25(OH)D is converted to the biologically active form, 1, 
25(OH)2D, by 1-α-hydroxylase in the kidney or some cells in non-renal compartments, such 
as cells of the immune system including T cells, B cells, macrophages and dendritic cells 
(Aranow, 2011). 
 
It has recently been recognised that vitamin D is a vital mediator of innate immune responses, 
enhancing the antimicrobial properties of immune cells such as monocytes and macrophages 
(Bikle, 2009). Vitamin D is a key link between TLR activation and antimicrobial responses in 
innate immunity. Following activation of the TLR signalling cascade in the presence of 
microbes, vitamin D has a vital role in up-regulating the production of AMPs, such as 
cathelicidin and β-defensin (Liu et al., 2006). The biologically active 1, 25(OH)2D binds to 
vitamin D receptors and induces expression of vitamin D responsive genes to enhance the 
production of cathelicidin and β-defensin (Wang et al., 2004). These AMPs have a broad 
range of activities against microorganisms and may be involved in the direct inactivation of 
viruses through membrane destabilization (Kamen & Tangpricha, 2010). They are produced 
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by epithelial cells and macrophages and in the lungs are secreted into the biofilm covering the 
inner surface of the airways, thereby creating a barrier that is chemically lethal to microbes. 
Recently, we demonstrated that vitamin D status influences the resting plasma cathelicidin 
(LL-37) concentration and salivary SIgA secretion rate in endurance athletes during a winter 
training period (He et al., 2013; chapter 3). The plasma cathelicidin concentration in athletes 
with high-level vitamin D concentrations was significantly higher than in athletes with low-
level vitamin D concentrations and there was a positive correlation between the plasma 
25(OH)D and cathelicidin concentrations. In addition, the averaged salivary SIgA secretion 
rate during the 4-month winter period in the individuals who had relatively high vitamin D 
concentrations (plasma 25(OH)D >120 nmol/L) was significantly higher than in groups 
having low vitamin D concentrations (<30 nmol/L). 
 
Vitamin D insufficiency has been reported to be common in athletes in the United Kingdom 
(UK) especially when training in the winter months (Close et al., 2013; Morton et al., 2012; 
He et al., 2013; chapter 3). Two studies that assessed the vitamin D status of UK-based 
professional athletes (latitude 53N) reported that 62% of athletes (38/61) including 
professional rugby players, soccer players and jockeys had inadequate serum total 25(OH)D 
concentrations (<50 nmol/L) in the winter months (Close et al., 2013) and 65% of elite soccer 
players in the English Premier League (13/20) presented with serum total 25(OH)D 
concentrations <50 nmol/L in December (Morton et al., 2012).In our previous study on a 
large student cohort of endurance athletes, we also found that 55% of endurance athletes 
(100/181) had serum total 25(OH)D concentrations  <50 nmol/L at the end of the 4-month 
winter training period (He et al., 2013; chapter 3). Given that the high prevalence of 
insufficient vitamin D status in athletes in the UK during winter months, it seems probable 
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that vitamin D supplementation could be desirable for athletes during this period to increase 
vitamin D concentrations to up-regulate the expression of AMPs and possibly reduce the risk 
of respiratory infections. 
 
The purpose of this study was to examine the effect of vitamin D3 supplementation (5000 
IU/day) over the winter months (from December to February, approximately 14 weeks) on 
the resting plasma cathelicidin concentration and the salivary concentrations and secretion 
rates of SIgA, cathelicidin, lactoferrin and lysozyme in a population of individuals engaged in 
regular sport training. It was hypothesized that participants could reach the 25(OH)D level of 
120 nmol/L after this duration of vitamin D3 supplementation and increase their resting 
salivary AMPs expression during the winter months. 
 
5.3 Methods 
Participants  
Fifty healthy men aged 20.4 ± 1.9 years who were engaged in regular sports training (such as 
rugby, volleyball, swimming, triathlon, cycling and racquet sports) from Loughborough 
University, UK (latitude 53N) volunteered to participate in the study during November 2013 
and their self-reported training loads (determined by a pre-screening questionnaire) averaged 
11 ± 4 h/week (mean ± SD). Participants were required to complete a comprehensive health-
screening questionnaire prior to starting the study and had not taken any regular medication 
or antibiotics in the 3 months prior to the study. All participants were fully informed about 
the rationale for the study and of all experimental procedures to be undertaken. Participants 
provided written consent to participate in the study, which had earlier received the approval 
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of Loughborough University ethical advisory committee. The details of inclusion and 
exclusion criteria were described in Chapter 2. Participants travelling overseas during the 
study period were also excluded. Participants were not allowed to take any other supplements, 
other than a daily multivitamin tablet providing no more than the recommended dietary 
allowances of essential vitamins. 
 
Study protocol 
Information about the study was given to the participants 1-2 weeks before their first visit to 
the laboratory. For the first visit to the laboratory, participants arrived in the morning at 
09:00-12:00 following a 3-h fast and their body mass and stature were recorded. Participants 
were required to abstain from any strenuous physical activity for 24 h before coming to the 
laboratory. Participants sat quietly for 10 min and completed a health-screening questionnaire 
and inclusion/exclusion criteria questionnaire before signing an informed consent form. 
Saliva and blood samples were collected as described in Chapter 2. 
 
The participants were randomly allocated to an intervention (vitamin D3 supplement) group 
or placebo group for 14 weeks in a double-blind fashion. The vitamin D3 group received a 
daily supplement of 5000 IU of vitamin D3 in capsule form, whereas the placebo group 
received a visually identical cellulose placebo capsule (Bio-Tech Pharmacal, Arkansas, USA). 
Participants were given a 7-week supply of vitamin D3 or placebo capsules and attended the 
laboratory again after 7 weeks to get another 7-week supply of supplement. Participants were 
also asked to fill in a standard short form of IPAQ (http://www.ipaq.ki.se/downloads.htm) at 
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weekly intervals, thus providing the quantitative information on training loads in MET-
h/week (Craig et al., 2003; Appendix B).  
 
Participants attended the laboratory after 7 and 14 weeks following a 3-h fast and their body 
mass was recorded again. Participants were also required to abstain from any strenuous 
physical activity for 24 h before coming to the laboratory. Blood samples were collected 
again at the end of the study and unstimulated saliva samples were collected after 7 and 14 
weeks. A total of 39 participants completed the study and provided sufficient blood for 
routine haematology and vitamin D status analysis at the start and end of the study and 
sufficient saliva (1 mL) for analysis of AMPs on all 3 occasions. 
 
Plasma analysis 
Plasma samples were analysed for total 25(OH)D and cathelicidin concentrations as 
described in Chapter 2.  
 
Saliva analysis 
The saliva volume collected and flow rate were estimated as described in Chapter 2. Saliva 
samples were analysed for SIgA, cathelicidin, lactoferrin and lysozyme as described in 
Chapter 2. Secretion rates for each of the salivary AMPs were calculated as described in 
Chapter 2. 
  
Statistical analysis 
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The Shapiro-Wilk test was used to determine if data sets were normally distributed. 
Anthropometric, self-reported training load (h/week), average IPAQ scores (MET-h/week) 
and haematological variables were compared between the vitamin D3 and placebo groups 
using unpaired t tests for normally distributed data or nonparametric Mann-Whitney U test 
for non-normally distributed data. Plasma total 25(OH)D and cathelicidin concentrations at 
the start and end of the study were assessed between the vitamin D3 and placebo groups using 
nonparametric Wilcoxon signed ranks test and Mann-Whitney U test. The percentage change 
of plasma cathelicidin concentration during the study period was also compared between two 
groups using nonparametric Mann-Whitney U test. The changes in the concentrations and 
secretion rates of salivary AMPs as well as the salivary flow rates over the 14 weeks of the 
study in the vitamin D3 and placebo groups were assessed by two-way ANOVA or 
nonparametric Friedman tests with post hoc Dunn’s test and Mann-Whitney U test. Data are 
presented as mean (±SD) for data sets that were normally distributed; for data sets that were 
not normally distributed, the median and IQR are shown. The accepted level of significance 
was P<0.05. 
 
5.4 Results 
Adherence to the study 
Thirty nine participants (vitamin D3: n=20; placebo: n=19) completed the study and provided 
sufficient blood for routine haematology and analysis of 25(OH)D and cathelicidin 
concentrations on 2 occasions and sufficient saliva for analysis of AMPs on all 3 occasions. 
Reasons for dropout were given as foreign travel (N=3), injury (N=6) or due to undisclosed 
reasons (N=2). 
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Baseline characteristics and physical activity levels 
There were no significant differences in baseline anthropometrics or haematological variables 
between the vitamin D3 and placebo groups (Table 5.1). Analysis of the IPAQ questionnaires 
indicated that the weekly training loads during the study period were relatively stable within 
the vitamin D3 and placebo groups. The training loads averaged over the study period were 
not significantly different between the vitamin D3 and placebo group (Table 5.1). Median 
(IQR) training loads were 69.0 (49.3-80.3) MET-h/week in the vitamin D3 group which is 
equivalent to about 11.4 h of moderate-vigorous activity per week and 78.2 (47.6-112.0) 
MET-h/week in the placebo group which is equivalent to about 12.9 h of moderate-vigorous 
activity per week.  
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Table 5.1 Anthropometric, training and haematological variables in the vitamin D3 and placebo groups at baseline and their training loads 
determined by IPAQ during the intervention period 
 
Vitamin D3 (n=20) Placebo (n=19) P 
Age (years) 20.1 ± 1.7 21.0 ± 2.3 0.168 
Stature (cm) 181.9 ± 6.9 182.2 ± 8.0 0.907 
Body mass (kg) 80.8 ± 13.1 80.0 ± 11.2 0.849 
BMI (kg/m
2
) 24.3 ± 3.1 24.1 ± 2.6 0.769 
Previous training load (h/week) 10.1 ± 4.0 11.1 ± 4.8 0.503 
IPAQ (MET-h/week) 69.0 (49.3-80.3) 78.2 (47.6-112.0) 0.374 
RBC count (x10
12
/L) 4.8 ± 0.3 4.9 ± 0.3 0.231 
Haematocrit (%) 44.1 ± 1.9 43.8 ± 2.5 0.687 
Haemoglobin (g/L) 148 ± 7 146 ± 7 0.546 
Leukocyte count (x10
9
/L) 5.5 ± 1.4 5.7 ± 1.2 0.707 
Data are shown as the mean ± SD or the median and IQR as appropriate. P values are from unpaired t tests apart from IPAQ training load where 
the Mann-Whitney U test for nonparametric data was used. 
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Plasma total 25(OH)D and cathelicidin concentrations 
The median plasma total 25(OH)D concentration increased from 54.5 to 125.5 nmol/L at 
week 14 in the vitamin D3 group (P=0.001) and decreased from 57.0 to 32.5 nmol/L in the 
placebo group at 14 weeks (P=0.001) (Table 5.2). At the end of the study there was a 
significant difference between groups (P<0.001). Although the median plasma cathelicidin 
concentration increased in both groups (vitamin D3: 29.5 to 34.0 ng/mL, P=0.003; placebo: 
30.9 to 33.6 ng/mL, P=0.048; Wilcoxon signed ranks test) (Table 5.2), the percentage change 
of cathelicidin concentration in the vitamin D3 group was higher than in the placebo group 
(vitamin D3: 15.0%; placebo: 5.4%, P=0.025; Mann-Whitney U test) (Figure 5.1).  
 
 
 
 
 
 
 
 
 
 
Figure 5.1 The percentage change of plasma cathelicidin concentration after the 14-week intervention period in 
the vitamin D3 supplement and placebo groups. Data are median and interquartile range. * Significant difference 
between groups (P=0.025; Mann-Whitney U test). 
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Table 5.2 Plasma total 25(OH)D and cathelicidin concentrations in the vitamin D3 and placebo groups before and after the 14-week intervention 
period 
  
Pre Post P 
Total 25(OH)D 
(nmol/L) 
 
Vitamin D3 54.5 (43.2-71.0) 125.5 (96.8-149.5) *  0.001 
Placebo 57.0 (38.7-71.0) 32.5 (26.7-49.3) 0.001 
Cathelicidin (g/L) 
 
Vitamin D3 29.5 (26.6-32.3) 34.0 (30.0-38.3) 0.003 
Placebo 30.9 (27.7-36.6) 33.6 (28.4-38.1) 0.048 
Data are shown as the median and IQR for nonparametric Wilcoxon signed ranks test. Significant difference between groups:  
* P < 0.001 based on Mann-Whitney U test. 
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Salivary variables 
While the concentrations of all salivary AMPs were not significantly altered over time in both 
vitamin D3 and placebo groups, the salivary flow rates increased over time in the vitamin D3 
group (Table 5.3). The resting SIgA and cathelicidin secretion rates increased over time in the 
vitamin D3 group (but not in the placebo group) (SIgA: 58.8, 87.2, 70.5 g/min, P=0.026; 
cathelicidin: 0.076, 0.103, 0.090 ng/min, P=0.030; Friedman tests) (Figure 5.2 a and b). 
Salivary lysozyme secretion rate increased over time in both groups (time, P=0.002; two-way 
ANOVA) but lactoferrin secretion rate was unaltered (Figure 5.2 c and d).  
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Figure 5.2 Changes in salivary secretion rates after 7 and 14 weeks of the intervention period in the vitamin D3 
supplement and placebo groups for (A) SIgA, (B) cathelicidin, (C) lysozyme and (D) lactoferrin. Data are 
shown as the mean ± SD (lysozyme) or the median and IQR (SIgA, cathelicidin and lactoferrin) as appropriate. 
The location of significant differences from week 0 within the vitamin D3 supplemented group only is indicated 
as follows: * P<0.05; † P=0.05 (Dunn’s post hoc test applied when Friedman test P<0.05). Significant 
difference from week 0 in both groups is indicated as follows: # P<0.05. 
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Table 5.3 Salivary flow rate and AMPs concentration in the vitamin D3 and placebo groups before and after 7 and 14 weeks of the intervention 
  
Week 0 Week 7 Week 14 P 
Saliva flow rate (L/min) 
Vitamin D3 317 (181-420)     462 (254-642) *    358 (274-640) * 0.022 
Placebo 260 (192-496) 331 (242-540) 352 (251-532) 0.143 
SIgA concentration (mg/L) 
Vitamin D3 183.8 (142.0-221.8) 170.3 (121.3-235.8) 171.1 (145.6-217.2) 0.861 
Placebo 181.3 (130.4-227.0) 141.4 (120.0-249.9) 171.9 (105.5-245.0) 0.211 
Lactoferrin concentration (g/L) 
Vitamin D3 4715 (2875-5861) 5358 (2995-7596) 4485 (2342-6810) 0.350 
Placebo 4274 (1483-5450) 3772 (1763-5087) 5874 (1235-7550) 0.692 
Lysozyme concentration (g/L) 
Vitamin D3 2472 ± 2515 2986 ± 2907 2397 ± 1644 
time*group, 0.460 
Placebo 3367 ± 3135 3205 ± 2500 3018 ± 2389 
Cathelicidin concentration (g/L) 
Vitamin D3 0.22 (0.09-0.53) 0.32 (0.13-0.45) 0.23 (0.09-0.45) 0.463 
Placebo 0.25 (0.05-0.94) 0.16 (0.07-0.37) 0.20 (0.07-0.28) 0.065 
Data are shown as the mean ± SD for two-way ANOVA or the median and IQR for nonparametric Friedman test with post hoc Dunn’s test. The location of 
significant differences from week 0 within the group is indicated as follows: * P<0.05 (Dunn’s post hoc test applied when Friedman test P<0.05). 
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5.5 Discussion 
As expected, plasma total 25(OH)D concentration significantly increased in the vitamin D3 
group and significantly decreased in the placebo group. The salivary SIgA and cathelicidin 
secretion rates significantly increased over time in the vitamin D3 group but not in the 
placebo group. In addition, the percentage change of plasma cathelicidin concentration in the 
vitamin D3 group was significantly higher than in the placebo group although plasma 
cathelicidin concentration significantly increased in both groups.  
 
We demonstrated that in athletes following 14 weeks of vitamin D3 supplementation with 
5000 IU/day there was a significant increase in the plasma total 25(OH)D concentration from 
54.5 to 125.5 nmol/L. This increase in total 25(OH)D is similar to a previous randomised 
placebo-controlled trial of 5000 IU daily vitamin D3 supplementation, where plasma 
25(OH)D levels increased significantly from 29 to 103 nmol/L in the intervention group after 
8 weeks of supplementation (Close et al., 2013). During the winter months, 5000 IU of 
vitamin D3 supplement daily could be a possible way for athletes to elevate 25(OH)D 
concentrations above a mean of 120 nmol/L as  a higher resting salivary SIgA secretion rate 
was found in the athletes with 25(OH)D >120 nmol/L during the winter period (He et al., 
2013; chapter 3). However, the supplementation period and dosage required to increase and 
maintain serum 25(OH)D concentration to a level necessary for optimal immune function in 
athletes are still unclear. In addition, it was also observed that plasma total 25(OH)D 
concentration significantly decreased in the placebo group from December to February 
probably reflecting seasonal changes and time from last effective ultraviolet exposure. 
Several other studies that assessed the plasma 25 (OH)D concentrations of UK-based athletes 
have shown that there was no change or a significant decrease in the plasma 25(OH)D levels 
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during the winter training period in athletes without vitamin D supplementation (Close et al., 
2013; Owens et al., 2014; He et al., 2013; chapter 3). This is most likely due to insufficient 
ultraviolet radiation of appropriate wavelength (290-315 nm) between November and March 
in the UK to produce vitamin D in the skin (Webb & Holick, 1988). 
 
In the present study the resting salivary SIgA and cathelicidin secretion rates significantly 
increased over time in the vitamin D3 group. To our knowledge, this is the first report to show 
a significant increase in the resting salivary SIgA secretion rates after a period of vitamin D3 
supplementation. The reasons for this are still unclear, but could be related to the elevated 
salivary flow rates after vitamin D3 supplementation. We report that the salivary flow rates 
significantly increased over time in the vitamin D3 group. Several animal studies have 
demonstrated that VDRs are present in the parotid, submandibular and sublingual salivary 
glands which suggest a possible role for vitamin D in regulation of salivary secretion. This is 
supported by the finding that salivary flow rates were stimulated after treatment with vitamin 
D3 in vitamin D-deficient rats (Peterfy, Tenenhouse, & Yu, 1988; Stumpf, 2008). Although 
the influence of vitamin D on salivary flow rate has not yet been demonstrated in humans, the 
finding that there was a significant positive correlation between plasma total 25(OH)D 
concentration and salivary flow rate in the endurance athlete cohort (N=225) (unpublished 
data, r=0.196, P=0.003; Pearson correlation test; He et al., 2013; chapter 3) might lend some 
support to this suggestion.  In addition,  the resting salivary SIgA and cathelicidin secretion 
rates in the vitamin D3 group slightly dropped from week 7 to week 14. The reasons for this 
are unknown. Further studies involving different durations of vitamin D3 supplementation are 
warranted to determine the effect on the responses of salivary AMPs. 
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We also found that salivary cathelicidin secretion rates only significantly increased in the 
participants with vitamin D3 supplementation. Human cathelicidin is expressed in neutrophils, 
epithelial cells and salivary glands and can be detected in whole saliva (Davison, Allgrove, & 
Gleeson, 2009; Murakami, Ohtake, Dorschner, & Gallo, 2002). The elevated salivary 
cathelicidin secretion rates might be due to the influence of 25(OH)D in the human oral 
epithelial cells. Human oral epithelial cells which express VDRs and 1-α-hydroxylase have 
the enzymatic machinery to convert 25(OH)D to 1, 25(OH)2D and it has been demonstrated 
that 25(OH)D can induce expression of the vitamin D responsive genes to enhance the 
production of cathelicidin by binding to VDRs  in dose-related manner in human oral 
keratinocytes (Wang et al., 2013). 
 
Our results indicate that 5000 IU of vitamin D3 supplement daily could have a beneficial 
effect in up-regulating plasma cathelicidin. We found that the percentage change of 
cathelicidin concentration in the vitamin D3 group was significantly higher than in the 
placebo group, although plasma cathelicidin concentration significantly increased in both 
groups from November to March. The reason for the increase of plasma cathelicidin 
concentration in the placebo group is unclear, but could be related to the likely higher 
respiratory infection incidence over the winter months as cathelicidin production is increased 
following pathogen exposure and TLR activation (Bucki, Leszczynska, Namiot, & 
Sokolowski, 2010). Moreover, there was a similar result in another vitamin D3 supplement 
study in which 25 healthy participants with plasma 25(OH)D concentration less than 80 
nmol/L ingested 50,000 IU vitamin D3 every other day, for 5 days, and a statistically 
significant increase of circulating cathelicidin concentration was only found in participants 
with 25(OH)D levels increasing more than 80 nmol/L after the vitamin D3 treatment (Bhan et 
al., 2011).  In our study, we also found a significant increase of plasma cathelicidin 
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concentration in the vitamin D3 group although there were only 5 participants with 25(OH)D 
levels increasing more than 80 nmol/L after supplementation. It has been reported that 
patients with the lowest circulating concentrations of cathelicidin undergoing dialysis are at a 
greater than two-fold increased risk of death from infectious causes (Gombart et al., 2009). 
Given the observed associations of circulating cathelicidin concentrations and infection-
associated mortality in human studies, a high dose of vitamin D3 supplementation might be 
clinically useful in the populations that may be more at risk of infection due to occupational 
or lifestyle stress (e.g. athletes and military personnel). 
 
Recently, it has been suggested that several salivary AMPs, such as SIgA and cathelicidin, 
might be associated with the incidence of URTI. Previous studies have shown an inverse 
relationship between SIgA values and URTI prevalence and low SIgA values have been 
reported to be associated with increased incidence of URTI in athletes (Fahlman & Engels, 
2005; Gleeson et al., 2012; Neville et al., 2008). A one-year follow-up study has reported that 
the number of URTI episodes was negatively correlated with salivary cathelicidin levels 
(Usui et al., 2012). Further studies are still needed to establish if the enhancement of salivary 
SIgA and cathelicidin secretion after vitamin D supplementation could reduce the risk of 
URTI in athletes. 
 
In conclusion, 5000 IU of vitamin D3 supplementation daily appears to have a beneficial 
effect in up-regulating the expression of SIgA and cathelicidin in athletes during a winter 
training period. Vitamin D supplementation, therefore, could have a positive effect on 
immune function and lead to decreased incidence of respiratory infections. Further research 
in a substantially larger athlete cohort is needed to determine this possibility. In addition, it is 
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still unknown whether participants could reach the 25(OH)D level of 120 nmol/L after a 
substantially shorter term of high dose vitamin D3 supplementation to elevate the resting 
expression of AMPs. 
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Chapter 6:  
The influence of vitamin D status and 4 weeks of vitamin 
D3 supplementation on salivary antimicrobial peptides 
and proteins responses to prolonged exercise 
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6.1 Abstract 
The purpose of this study was to determine the influence of vitamin D status and a short term 
of daily high dose vitamin D3 supplementation on the salivary concentrations and secretion 
rates of SIgA, cathelicidin and human neutrophil peptides (HNP) 1-3 in response to 
prolonged and moderate intensity exercise. Fourteen healthy men cycled for 2 h at 60 % VO2 
max. Unstimulated saliva and blood samples were taken at pre-exercise and the further saliva 
samples were taken at post- exercise and 1 h post-exercise. After this trial, 7 participants 
received a daily supplement of three 5000 IU vitamin D3 capsules for 4 weeks and then 
cycled for 2 h at 60% VO2max again. Unstimulated saliva and blood samples were taken as 
before. The data showed that there were no significant interaction effects for the 
concentrations and secretion rates of AMPs in the high-level and low-level vitamin D groups. 
Although the total 25(OH)D concentrations of participants with vitamin D3 supplementation 
increased from 66.3 ± 16.6 to 151.5 ± 27.4 nmol/L, there were no significant interaction 
effects for the concentrations and secretion rates of AMPs in the pre-intervention and post-
intervention trials. We found that there were no significant effects of vitamin D status and a 
4-week period of vitamin D3 supplementation on the salivary AMPs responses to prolonged 
exercise. However, further studies including more participants with a larger range of vitamin 
D status or a longer period of vitamin D3 supplementation are warranted. 
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6.2 Introduction 
Prolonged bouts of strenuous exercise could have a temporary negative impact on both 
aspects of innate immunity and acquired immunity. Post-exercise immune function 
depression is most pronounced when the exercise is continuous, prolonged (longer than 1.5 h), 
of moderate to high intensity (55–75% VO2max), and performed without food intake 
(Gleeson, 2006). It has been reported that salivary AMPs increased significantly after 
prolonged exercise, such as cathelicidin and HNP 1-3 (Davison et al., 2009). 
 
It has recently been recognised that vitamin D is a vital mediator of innate immune responses, 
enhancing the antimicrobial properties of immune cells such as monocytes and macrophages 
(Bikle, 2009). Vitamin D is a key link between TLR activation and antimicrobial responses in 
innate immunity. Following activation of the TLR signalling cascade in the presence of 
microbes, vitamin D has a vital role in up-regulating the production of AMPs, such as 
cathelicidin (Liu et al., 2006). These AMPs have a broad range of activities against 
microorganisms and may be involved in the direct inactivation of viruses through membrane 
destabilization (Kamen & Tangpricha, 2010). They are produced by epithelial cells and 
macrophages and in the lungs are secreted into the biofilm covering the inner surface of the 
airways, thereby creating a barrier that is chemically lethal to microbes. A recent study in 
university athletes reported a higher level of plasma cathelicidin and salivary SIgA secretion 
in those who had plasma 25(OH)D greater than 120 nmol/L compared with those who had 
lower vitamin D status (He et al., 2013; Chapter 3) and a follow-up randomised, placebo 
controlled, double blind vitamin D3 supplementation study (5000 IU/day for 14 weeks) by the 
same group (He et al., 2015; Chapter 5) reported significant increases in salivary secretion 
rates of both SIgA and cathelicidin compared with no significant change in the placebo group. 
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This was due, at least in part to a significant increase in the saliva flow rates over time in the 
vitamin D group.  
 
However, the relationships between vitamin D status, salivary AMPs, saliva flow rates and 
prolonged exercise have not yet been explored. Also it is still unknown whether participants 
could reach the 25(OH)D level of 120 nmol/L after a relatively short term period of daily 
high dose vitamin D3 supplementation. Therefore, the purpose of this preliminary study was 
to determine the influence of vitamin D status and a month of daily high dose vitamin D3 
supplementation on the salivary concentrations and secretion rates of SIgA, cathelicidin and 
HNP1-3 in response to prolonged and moderate intensity exercise in a population of 
individuals engaged in regular sport training. We hypothesized that all participants would 
reach the 25(OH)D level of 120 nmol/L after vitamin D3 supplementation to elevate their 
resting salivary AMPs expression and that participants with high level of vitamin D 
concentrations would exhibit enhanced salivary AMPs expression  in response to prolonged 
exercise 
 
6.3 Methods 
Participants  
Fourteen healthy men (age: 22.9 ± 3.4 years, body mass: 79.8 ± 8.7 kg, height: 184.2 ± 7.3 
cm, body mass index: 23.6 ± 2.5 kg/m
2
 and VO2 max: 55.9 ± 13.6 ml/kg/min) who were 
engaged in regular sports training from Loughborough University, UK (latitude 53 N) 
volunteered to participate in the study during May to July 2014 and their self-reported 
training loads (determined by a pre-screening questionnaire) averaged 12 ± 5 h/week (mean ± 
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SD). Participants were required to complete a comprehensive health-screening questionnaire 
prior to starting the study and had not taken any regular medication or antibiotics in the 3 
months prior to the study. All participants were fully informed about the rationale for the 
study and of all experimental procedures to be undertaken. Participants provided written 
consent to participate in the study, which had earlier received the approval of Loughborough 
University ethical advisory committee. The details of inclusion and exclusion criteria were 
described in Chapter 2. 
 
Study protocol 
Approximately 1 week before the main trials, participants completed a continuous 
incremental test on an electromagnetically braked cycle ergometer (Lode Excalibur Sport, 
Groningen, Netherlands) to volitional exhaustion to determine their maximal oxygen uptake 
(VO2 max). After a 3-min warm-up cycling at 70 W, the test began at 95 W with increments 
of 35 W every 3 min. Verbal encouragement was provided to ensure maximal effort. Expired-
gas samples were collected in Douglas bags (Harvard Apparatus, Edenbridge, UK) during the 
third minute of each work-rate increment, and heart rate was measured continuously using 
short-range radio telemetry (Polar, Kempele, Finland). An oxygen/carbon dioxide analyzer 
(Servomex 1400, Crowbridge, UK) was used along with a dry gas meter (Harvard Apparatus, 
Edenbridge, UK) to determine VE, VO2, and VCO2. From the VO2–work-rate relationship, 
the work rate equivalent to 60% VO2 max was interpolated. After a 15 minute recovery, 
participants cycled for 20 min at a steady state work rate equivalent to 60 % VO2 max with 
expired gas samples collected after 10 and 20 min in order to familiarize the subjects with the 
exercise protocol for subsequent trials and to ensure that the calculated work rate elicited the 
desired. After this trial the participants were familiarized with the saliva-collection procedure.  
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For the main trials, all the participants arrived at 12:00 following a 3-h fast and their body 
mass and stature were recorded. Participants were required to abstain from any strenuous 
physical activity for 24 h before coming to the laboratory. Saliva and blood samples were 
collected as described in Chapter 2. Participants then cycled for 120 min at 60% VO2 max on 
a stationary cycle ergometer in a laboratory maintained at 21 ± 1 ºC and drank water ad 
libitum during exercise. Expired gas was collected after 15, 45, 75, and 105 min of exercise 
to determine VO2. Heart rate was measured using short-range telemetry (Polar, Kempele, 
Finland) at 30-min intervals. Immediately after completing the exercise task, unstimulated 
saliva samples were taken. Another saliva samples were taken at 60 minutes after exercise. 
After centrifugation for 2 min at 5000 g to remove cells and insoluble matter, the saliva 
samples were stored frozen at -20 ºC prior to analysis. The EDTA blood was centrifuged for 
10 min at 1500 g and 4 ºC and the plasma stored at -20ºC prior to analysis. 
 
After the main trials, participants were randomly allocated to a vitamin D3 supplement group 
(n=7)  or a placebo group (n=7); those in the supplemented group received a daily 
supplement of three 5000 IU vitamin D3 capsules (one at breakfast, one at lunch and one at 
dinner); those in the placebo group received 3 placebo (cellulose) capsules. After the 4-week 
supplementation period, the participants returned to the laboratory at 12:00 following a 3-h 
fast and their body mass and stature were recorded again. They were also required to abstain 
from any strenuous physical activity for 24 h before coming to the laboratory. A resting 
unstimulated saliva sample and venous blood sample (10 ml) were taken as before. During 
the second main trial, the participants in the vitamin D3 supplement group performed the 
same exercise, 120 min cycling at 60% VO2 max and further saliva samples were taken as 
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before. Two of the participants in the placebo group dropped out and the remaining 5 
participants had a resting blood sample taken after 4 weeks as the control group for plasma 
25(OH)D concentration. 
 
Plasma analysis 
Plasma samples were analysed in duplicate for total 25(OH)D concentrations. The best 
measure of vitamin D status is considered to be the sum of the 25-hydroxy metabolites of D2 
and D3 (25(OH)D3 and 25(OH)D2). The resting EDTA plasma samples were assayed in 
duplicate for 25(OH)D concentration using a commercially available immunoassay kit 
(25(OH)-Vitamin D Xpress ELISA kit K2107, Immunodiagnostik AG, Bensheim, Germany) 
according to the manufacturer’s instructions which has been shown by the manufacturer to 
have excellent agreement (R
2=0.920) with the ‘gold-standard’ high pressure liquid 
chromatography-tandem mass spectrometer method. It has also shown a good agreement 
(R
2
=0.832) from our own samples that we analysed with both methods prior to the study. The 
intra-assay CV was ±5.1% across a working range of 16–250 nmol/L. Plasma samples were 
also analysed for cathelicidin concentrations as described in Chapter 2. 
 
Saliva analysis 
The saliva volume collected and flow rate were estimated as described in Chapter 2. Saliva 
samples were analysed for SIgA, cathelicidin and HNP1-3 as described in Chapter 2. 
Secretion rates for each of the salivary AMPs were calculated as described in Chapter 2. 
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Statistical analysis 
The Shapiro-Wilk test was used to determine if data sets were normally distributed. 
Anthropometric, haematological variables, self-reported training loads, VO2 max, 
physiological variables and total 25(OH)D concentrations were compared between the high-
level and low-level vitamin D groups using unpaired t tests. The changes in the 
concentrations and secretion rates of salivary AMPs as well as the salivary flow rates over the 
exercise trial in the high-level and low-level vitamin D groups were assessed by two-way 
mixed ANOVA. To compare the pre-intervention and post-intervention trials, the paired t test 
and two-way repeated measures ANOVA were used. Data are presented as mean (±SD) and 
the accepted level of significance was P<0.05. 
 
6.4 Results 
The plasma total 25(OH)D concentrations 
The total 25(OH)D concentration at baseline from 14 participants was 73.2 ± 26.8 nmol/L. 
The total 25(OH)D concentration from 5 participants classified in the high-level (>80 nmol/L) 
group was 102.7 ± 17.8 nmol/L and the total 25(OH)D concentration from 5 participants 
classified in the low-level (<60 nmol/L) was 49.9 ± 13.5 nmol/L. The total 25(OH)D 
concentrations from 4 participants excluded in these two group were 66.9, 66.6, 66.5 and 61.7 
nmol/L. 
 
In addition, the total 25(OH)D concentrations of 7 participants with vitamin D3 
supplementation increased from 66.3 ± 16.6 to 151.5 ± 27.4 nmol/L (P<0.001) and the total 
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25(OH)D concentrations from 5 participants without vitamin D3 supplementation were 
unaltered (63.5 ± 23.0 to 66.1 ± 21.2 nmol/L, P=0.531). 
 
Physiological and salivary variables in the high-level and low-level vitamin D groups  
There were no significant differences in baseline anthropometrics, haematological variables, 
training loads and VO2max between the high-level and low-level vitamin D groups (Table 
6.1). The mean relative exercise intensity (% VO2 max), power output and water intake over 
the 2 h exercise are also illustrated in Table 6.1 and there were no significant differences in 
any of the physiological variables during the trial between the two groups. 
 
Table 6.1 Physiological variables in the high-level and low-level vitamin D groups 
  High-level Low-level P 
Age (years)  22.4 ± 2.1 25.0 ± 4.5  0.272 
Height (cm) 180.2 ± 8.3 187.2 ± 5.0  0.140 
Body mass (kg) 77.9 ± 4.8 80.0 ± 11.2  0.579 
BMI (kg/m
2
) 24.2 ± 2.9 23.0 ± 2.4  0.521 
RBC count (x10
12
/L) 4.2 ± 0.5 4.3 ± 0.6 0.688 
Haematocrit (%) 38.7 ± 4.1 39.6 ± 5.7 0.781 
Haemoglobin (g/L) 142 ± 6 145 ± 13 0.694 
Leukocyte count (x10
9
/L) 6.5 ± 2.5 5.1 ± 1.1 0.296 
Training load (h/week) 11.4 ± 2.6 8.6 ± 2.2  0.103 
VO2 max (ml/kg/min) 55.0 ± 8.0 55.3 ± 13.1 0.966 
% VO2 max 57.2 ± 0.7 59.1 ± 3.4 0.250 
Power output (W) 182 ± 44 184 ± 37 0.940 
Water intake (ml) 1116 ± 635 1192 ± 744 0.866 
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There were no significant interaction effects for the concentrations and secretion rates of 
SIgA, cathelicidin and HNP1-3 although there were significant overall effects of time for the 
concentrations of SIgA, cathelicidin and HNP1-3 and the secretion rates of cathelicidin, all of 
which were inceased from pre- to post-exercise (Table 6.2). In addition, there were no 
significant overall effects of group for the concentrations and secretion rates of SIgA, 
cathelicidin and HNP1-3 between the high-level and low-level vitamin D groups (Table 6.2). 
Furthermore, there were no any significant effects for salivary flow rates (Table 6.2). 
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Table 6.2 Salivary variables during exercise in the high-level and low-level vitamin D groups 
    Pre-Ex Post-Ex 1 h Post-Ex 
Main Effects P values 
(group; time; group x time) 
Saliva flow rate (mL/min) High-level 0.504 ± 0.178 0.345 ± 0.143 0.406 ± 0.137 
0.492; 0.131; 0.223 
  Low-level 0.331 ± 0.246 0.307 ± 0.199 0.373 ± 0.240 
SIgA concentration (mg/L) High-level 159.3 ± 55.4 251.2 ± 60.7 264.8 ± 84.4 
0.343; 0.026; 0.952 
  Low-level 243.8 ± 123.9 316.5 ± 180.9 331.5 ± 195.7 
SIgA secretion rate (µg/min) High-level 73.9 ± 15.1 82.1 ± 23.2 110.2 ± 59.8 
0.475; 0.079; 0.941 
 
Low-level 65.5 ± 31.6 70.0 ± 34.9 92.4 ± 39.4 
Cathelicidin concentration (µg/L) High-level 4.0 ± 3.0 15.5 ± 3.1 14.0 ± 6.4 
0.360; 0.001; 0.094 
  Low-level 7.0 ± 4.7 11.6 ± 5.5 9.1 ± 4.2 
Cathelicidin secretion rate (ng/min) High-level 1.9 ± 1.4 5.1 ± 1.3 5.7 ± 3.0 
0.128; 0.010; 0.076 
 
Low-level 2.1 ± 1.8 3.1 ± 2.5 2.6 ± 0.7 
HNP 1-3 concentration (µg/L) High-level 310 ± 435 1272 ± 680 984 ± 897 
0.381; 0.043; 0.140 
  Low-level 1234 ± 1097 1422 ± 904 1165 ± 660 
HNP 1-3 secretion rate (ng/min) High-level 138.5 ± 186.7 411.1 ± 242.8 367.9 ± 357.9 
0.931; 0.064; 0.300 
  Low-level 282.2 ± 212.4 355.1 ± 293.4 317.0 ± 180.7 
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Physiological and salivary variables in the pre-intervention and post-intervention trials 
Seven participants (age: 24.3 ± 3.9 years, body mass: 78.3 ± 7.3 kg, height: 186.7 ± 4.3 cm, 
body mass index: 22.5 ± 1.9 kg/m
2
 and VO2 max: 57.0 ± 12.2 ml/kg/min)  received a 4-week 
period of 15000 IU daily vitamin D3 supplementation and then performed the same exercise 
trial.  
 
There were no significant differences in baseline haematological variables between pre-
intervention and post-intervention trials. The mean exercise intensity (% VO2 max), power 
output and water intake over the 2 h exercise were illustrated in Table 6.3 and there were no 
significant differences in any physiological variables during 2 h exercise between pre-
intervention and post-intervention trials. 
 
Table 6.3 Physiological variables in the pre-intervention and post-intervention trials 
  PRE-Intervention POST-Intervention P 
RBC count (x10
12
/L) 4.3 ± 0.6 4.6 ± 0.2 0.168 
Haematocrit (%) 39.4 ± 5.4 42.4 ± 1.7 0.165 
Haemoglobin (g/L) 140 ± 7 136 ± 7 0.057 
Leukocyte count (x10
9
/L) 4.8 ± 1.0 4.3 ± 0.6 0.071 
% VO2max 59.1 ± 3.1 58.9 ± 3.2 0.889 
Power output (W) 197 ± 36 197 ± 36 1.000 
Water intake (ml) 1226 ± 734 1236 ± 414 0.960 
 
 
 
Chapter 6                                                                               Vitamin D and prolonged exercise 
126 
 
There were no significant interaction effects for the concentrations and secretion rates of 
SIgA, cathelicidin and HNP1-3 although there were significant overall effects of time for the 
concentrations of SIgA, cathelicidin and HNP1-3 which all increased from pre- to post-
exercise (Table 6.4). In addition, there were no significant overall effects of trial for the 
concentrations and secretion rates of SIgA, cathelicidin and HNP1-3 between pre-
intervention and post-intervention trials (Table 6.4). Furthermore, there were no any 
significant effects for salivary flow rates (Table 6.4). 
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Table 6.4 Salivary variables during exercise in the pre-intervention and post-intervention trials 
    Pre-Ex Post-Ex 1 h Post-Ex 
Main Effects P values    
(trial; time; trial x time) 
Saliva flow rate (mL/min) 
PRE-Intervention 
0.374 ± 0.191 0.314 ± 0.141 0.377 ± 0.178 
0.186; 0.211; 0.255 
  
POST-Intervention 
0.435 ± 0.204 0.360 ± 0.145 0.508 ± 0.201 
SIgA concentration (mg/L) 
PRE-Intervention 
248.3 ± 117.7 339.2 ± 192.5 306.5 ± 133.0 
0.184; 0.041; 0.427 
  
POST-Intervention 
230.3 ± 71.7 307.4 ± 177.0 213.9 ± 110.8 
SIgA secretion rate (g/min) PRE-Intervention 75.1 ± 19.0 89.6 ± 40.8 101.2 ± 34.0 
0.459; 0.564; 0.793 
 
POST-Intervention 
93.4 ± 39.0 103.1 ± 56.6 100.8 ± 57.0 
Cathelicidin concentration (g/L) PRE-Intervention 7.4 ± 5.3 14.9 ± 7.3 8.6 ± 3.1 
0.161; 0.044; 0.447 
  
POST-Intervention 
7.8 ± 6.8 10.6 ± 3.8 6.7 ± 6.5 
Cathelicidin secretion rate (ng/min) 
PRE-Intervention 
2.3 ± 1.7 4.2 ± 2.2 2.9 ± 0.9 
0.545; 0.226; 0.924 
 
POST-Intervention 
2.7 ± 2.1 4.1 ± 2.9 3.3 ± 3.0 
HNP 1-3 concentration (g/L) PRE-Intervention 1085.9 ± 1070.5 1481.9 ± 911.8 874.0 ± 568.1 
0.259; 0.023; 0.771 
  
POST-Intervention 
855.3 ± 773.7 1202.3 ± 1045.2 811.4 ± 688.5  
HNP 1-3 secretion rate (ng/min) 
PRE-Intervention 
272.1 ± 220.6 399.7 ± 248.6 275.6 ± 166.1 
0.630; 0.229; 0.665 
  
POST-Intervention 
250.7 ± 216.3 415.7 ± 340.3 376.0 ± 352.3 
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6.5 Discussion  
This was a preliminary study to investigate the influence of vitamin D status and a short-term 
of vitamin D3 supplementation on salivary AMP responses to prolonged exercise. The main 
findings of the present study were as follows: (1) there were no significant interaction effects 
for the salivary flow rates as well as the concentrations and secretion rates of SIgA, 
cathelicidin and HNP1-3 between the high-level and low-level vitamin D groups; (2) the 
plasma total 25(OH)D concentrations significantly increased after a 4-week period of vitamin 
D3 supplementation; (3) there were no significant interaction effects for salivary flow rates or 
the concentrations and secretion rates of SIgA, cathelicidin and HNP1-3 between pre-
intervention and post-intervention trials. 
 
To our knowledge, this is the first study to examine the influence of vitamin D status on 
salivary AMP responses to prolonged exercise. We found that there were no significant 
interaction effects on the any salivary variable responses to prolonged exercise between the 
high-level and low-level vitamin D groups. It has been previously reported that vitamin D 
status influences the salivary SIgA secretion rates in endurance athletes during a winter 
training period (He et al., 2013; chapter 3). The median SIgA secretion rate during the 4-
month winter period in the individuals who had relatively high vitamin D concentrations 
(plasma 25(OH)D >120 nmol/L) was significantly higher than in groups having lower 
vitamin D status. However, in the present study, there was no significant effect of vitamin D 
status on the SIgA secretion rates at rest or in response to prolonged exercise. This is likely 
because the difference of plasma total 25(OH)D concentrations classified in the high-level 
group in the present study from the previous study. But it is worthy of note that the 
participants with higher vitamin D status tended to have higher SIgA, cathelicidin and HNP1-
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3 secretion rates at baseline and after exercise than those had lower vitamin D status in the 
present study and a significant limitation of the present study was the relatively small number 
of participants. Further research including more participants with a larger range of vitamin D 
status might be warranted to understand the effect of vitamin D status on the salivary AMP 
responses to prolonged exercise. In addition, we reported that the concentrations of SIgA, 
cathelicidin and HNP1-3 significantly increased after exercise in both the high-level and low-
level vitamin D groups, which is in accordance with previous studies involving prolonged 
exercise (Allgrove et al., 2009; Davison et al., 2009). 
 
On the basis of the present data, we found that the plasma total 25(OH)D concentrations 
significantly increased from 66.3 ± 16.6 to 151.5 ± 27.4 nmol/L after a 4-week period of 
15000 IU daily vitamin D3 supplementation. It was also observed that the total 25(OH)D 
concentrations from participants without vitamin D3 supplementation were unaltered from 
May to July. It seems likely that the sunlight from May to July in the UK is only enough to 
maintain vitamin D status instead of increasing the total 25(OH)D concentrations. A 
randomised, placebo controlled, double blind vitamin D3 supplementation study (5000 IU/day 
for 14 weeks) reported significant increases in salivary secretion rates of both SIgA and 
cathelicidin compared with no significant change in the placebo group (He et al., 2015; 
Chapter 5). Moreover, it has been shown that the resting salivary flow rates were increased 
after 7 and 14 weeks of  5000 IU daily vitamin D3 supplementation (He et al., 2015; Chapter 
5). However, in the present study there were no significant interaction effects for salivary 
flow rates and the expression of AMPs between pre-intervention and post-intervention trials. 
It might be due to the shorter period of vitamin D3 supplementation in the present study. 
Nevertheless, the salivary flow rates and the secretion rates of SIgA and cathelicidin tended 
to increase at baseline after 4 weeks of vitamin D3 supplementation. Therefore, the further 
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study of vitamin D3 supplementation for a longer period is needed to clarify the effects of 
vitamin D3 supplementation on the salivary AMP responses to prolonged exercise. 
 
We acknowledge that there were limitations in this pilot study design regarding the 
supplemental dose of vitamin D3 used and possible adverse responses. We used the dose of 
15,000 IU/day which is 50% higher than the European Food Safety Authority’s recently 
revised tolerable upper intake level of 10,000 IU/day. Also we did  not  measure any markers 
of  vitamin D toxicity. However, no participants in the current trial reported any of the 
symptoms of vitamin D toxicity which are attributable to hypercalcaemia, including nausea, 
dehydration and lethargy. Furthermore, both the IoM and the Endocrine Society concluded 
that the upper limit of 25(OH)D concentration of 250 nmol/L was safe and would not cause 
vitamin D intoxication (IoM, 2011; Holick et al., 2011). 
 
In summary, the results of current study showed that there were no significant effects of 
vitamin D status and a 4-week period of vitamin D3 supplementation on the salivary AMP 
responses to prolonged exercise. However, further studies including more participants with a 
larger range of vitamin D status or a longer period of vitamin D3 supplementation are 
warranted. 
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7.1 Overview of the experimental studies in this thesis 
 
Figure 7.1 Overview of the experimental studies  
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7.2 The main findings of the thesis 
The main findings in Chapter 3 were:  
 The female athletes had more URTI days and their URTI episodes lasted several days 
longer than the male athletes.  
 Saliva flow rate was ~17% lower in female athletes and the secretion rates of lactoferrin 
and lysozyme were significantly lower in females.  
 In both sexes, saliva AMP secretion rates increased over time which could be due to the 
significant fall in the training loads of the athletes that was observed in the middle part 
of the study period. 
 There was no difference in the proportion of subjects who presented with symptoms of 
infection between CMV/EBV positive and negative groups. 
 Athletes with prior infection of both CMV and EBV had fewer URTI episodes and 
symptom days and higher numbers of circulating lymphocytes than athletes who were 
seronegative for both CMV and EBV. 
 A higher proportion (67%) of athletes who had vitamin D concentrations (<30 nmol/L) 
experienced one or more URTI episodes during the 4-month study period. 
 The plasma cathelicidin concentration was positively associated with vitamin D 
concentrations.  
 The averaged salivary SIgA secretion rate during the 4-month winter period in athletes 
who had vitamin D concentrations (>120 nmol/L) was significantly higher than in 
groups having vitamin D concentrations (<30 nmol/L). 
 Pro-inflammatory cytokine production in response to multi-antigen stimulation was 
substantially lower in athletes who had vitamin D concentrations (<30 nmol/L). 
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The main findings in Chapter 4 were: 
 The circulating IL-10 and IFN- concentrations were significantly higher in the vitamin 
D sufficient athletes (>50 nmol/L) compared with the vitamin D insufficient athletes 
(<50 nmol/L). 
 The production of TNF-, IL-6, IFN-, IL-2 and IL-10 by multi-antigen stimulated 
whole blood culture were significantly influenced by 1, 25(OH)2D3 of concentrations of 
1000 pmol/L and/or 10000 pmol/L.  
 The production of lymphocyte-derived and monocyte-derived cytokines, such as IFN-, 
IL-2, IL-4 and IL-1, were significantly different in the multi-antigen stimulated whole 
blood culture without the addition of 1, 25(OH)2D3 compared with its production in the 
PBMC culture. 
The main findings in Chapter 5 were: 
 The salivary SIgA and cathelicidin secretion rates significantly increased over time in 
the vitamin D3 group but not in the placebo group.  
 The salivary flow rates increased over time in the vitamin D3 group but not in the 
placebo group. 
 The change of plasma cathelicidin concentration in the vitamin D3 group was 
significantly higher than in the placebo group. 
The main findings in Chapter 6 were: 
 There were no significant interaction effects for the salivary flow rates and AMPs 
responses to prolonged exercise between the high-level and low-level vitamin D 
participants. 
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 The plasma total 25(OH)D concentrations significantly increased after a short term of 
high dose vitamin D3 supplementation.  
 There were no significant interaction effects for the salivary flow rates and AMPs 
responses to prolonged exercise between pre-intervention and post-intervention trials. 
 
7.3 The limitations of the thesis 
 The phase of the menstrual cycle (when blood and saliva samples were taken) was not 
determined in this research but we did establish that 40% of the females were taking oral 
contraceptives.  
 We did not attempt to distinguish between symptoms of an infectious/illness nature vs 
inflammation throughout the winter months of the study design. We used the validated 
Jackson score questionnaire which is a conservative instrument requiring a substantial 
symptom score criterion threshold to define a URTI episode. 
 The participants’ plasma concentration of 1, 25(OH)2D was not determined in the study 
that we added different doses of 1, 25(OH)2D in the multi-antigen stimulated whole 
blood culture and the lower doses of 1, 25(OH)2D within the normal physiological range 
could be used in the whole blood culture. 
 There was a limitation in the pilot study design regarding supplemental dose. We used 
the dose of 15,000 IU/day which is 50% higher than the European Food Safety 
Authority’s recently revised tolerable upper intake level of 10,000 IU/day. However, no 
participants in the current trial had a plasma 25(OH)D concentration higher than 250 
nmol/L. Both the IoM and the Endocrine Society concluded that an upper limit of 
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25(OH)D concentration of 250 nmol/L was safe and would not cause vitamin D 
intoxication (IoM, 2011; Holick et al., 2011). 
 
7.4 Future directions 
Following on from the studies presented in this thesis, a number of key questions still remain 
to be answered: 
 Is it possible that the same training load could have a greater depressive effect on 
humoral and systemic immunity (e.g. lower secretion rates of mucosal AMPs and fewer 
numbers of circulating B cells and NK cells) for women than for men? 
 Further research is needed to understand the influence of previous CMV or EBV 
infection (or both)  on the immune system and clarify whether it has an important 
influence on the risk of URTI. 
 It is unknown that the influence of prior infection with CMV and EBV alone or in 
combination on the white blood cell subsets and salivary antimicrobial proteins response 
to prolonged exercise. 
 Is there an optimal vitamin D level for athletes to improve immune function and prevent 
URTI during the winter months? 
 Further research is needed to understand the effect of the normal healthy range or lower 
levels of plasma 1, 25(OH)2D on multi-antigen stimulated cytokine production by whole 
blood culture. 
 Different durations of vitamin D3 supplementation are warranted to determine the effects 
on the responses of salivary AMPs. 
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 It is still unknown if the enhancement of salivary SIgA and cathelicidin secretion after 
vitamin D3 supplementation could reduce the risk of URTI in athletes. 
 Further research including a large cohort of participants with various ranges of vitamin 
D status might be warranted to understand the effect of vitamin D status on the salivary 
AMP responses to prolonged exercise. 
 
7.5 Conclusions 
A series of studies in this thesis have demonstrated the influence of various factors (sex 
differences, CMV/EBV serostatus and vitamin D status) on susceptibility to URTI among 
athletes. Female athletes may be more susceptible than their male counterparts to URTI 
during winter training periods. Moreover, athletes who had experienced prior infection with 
both CMV and EBV may have fewer URTI episodes than those with negative serostatus for 
both CMV and EBV. In addition, athletes with low vitamin D status may have a higher risk 
of URTI and suffer more severe symptoms when URTI is present. Furthermore, it was 
suggested in this thesis that vitamin D3 supplementation could have a positive effect on 
immune function and lead to decreased incidence of respiratory infections. 
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Appendix A: Jackson Score Common Cold Symptom Questionnaire 
 
Name ..............................................Subject Number……. Date………………….. 
Do you think that you are suffering from a common cold or flu today?   
Fill in the circle if your answer is YES o 
 
If yes please complete all the questions below-   
Are any of the following symptoms of the common cold or flu present today? Please 
indicate your response by filling in one circle for each of the following symptoms: 
 
 
SYMPTOM         DEGREE OF DISCOMFORT            
 
        None at all  Mild    Moderate      Severe         
Sneezing        o  o  o  o           
 
Headache    o  o  o  o  
           
Malaise    o  o  o  o 
(feeling of being generally unwell,  
 run down or out of sorts) 
     
Nasal discharge   o  o  o  o            
(runny nose) 
 
Nasal obstruction   o  o  o  o  
(blocked nose)           
Sore throat    o  o  o  o            
 
Cough     o  o  o  o          
 
Fever     o  o  o  o 
 
Hoarseness    o  o  o  o 
 
Earaches    o  o  o  o 
 
Chilliness  
(question in Jackson original) o  o  o  o   
 
Joint aches and pains  o  o  o  o    
 
 
Have you taken your supplement today? Fill in the circle if your answer is YES o
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Appendix B: International Physical Activity Questionnaire 
 
Name ...............................................      Subject Number……. Date………………….. 
 
The following questions relate to the amount of physical activity you have undertaken in 
the past week. 
 
For the previous 7 days, please consider the amount, type and intensity of physical 
activity/training that you have undertaken. If this is more or less than normal, this 
should be reflected in your answers. This type of activity can take any form and can 
include normal everyday activities such as walking to the shops. 
 
Vigorous physical activity refers to activities that take hard physical effort to complete and 
make you breathe/work much harder than normal.  
 
Moderate activities refer to activities that take moderate physical effort and make you breathe 
somewhat harder than normal. 
 
If in training, try to classify each whole session as either vigorous or moderate and record 
appropriately in the boxes provided. 
 
Be as honest as possible. 
 
1. In the last seven days, on how many days did you partake in vigorous physical activities 
like heavy lifting, aerobics, hard training, cycling, swimming or running? 
 
 
 
2. On days when you did vigorous physical activity how much time did you usually spend 
doing it? 
 
 
 
3. In the last 7 days, on how many days did you partake in moderate physical activities like 
lifting light loads, moderate training, cycling, swimming or running? 
 
 
 
 
Days 
Hours Minutes 
Days 
If none, answer 00 and skip to question 3 
If none, answer 00 and skip to question 5 
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4. On days when you did moderate physical activity how much time did you usually spend 
doing it? 
 
 
 
5. In the last 7 days, on how many days did you walk for at least 10 minutes at a time? 
 
 
 
6. On days when you walked for at least 10 minutes at a time, in total, how much time did 
you spend walking? 
 
 
 
7. How much time did you spend sitting on a usual day? This may include time spent 
studying, visiting friends, reading or watching television. 
 
 
 
 
 
Hours Minutes 
Days 
Hours Minutes 
Hours Minutes 
If none, answer 00 and skip to question 7 
